Investigation of the P13K/AKT/FOXO and the Ras/Raf/MEK/ERK Signalling Pathways in Ovarian Development by Wynne, Claire
Technological University Dublin 
ARROW@TU Dublin 
Masters Science 
2009-06-01 
Investigation of the P13K/AKT/FOXO and the Ras/Raf/MEK/ERK 
Signalling Pathways in Ovarian Development 
Claire Wynne 
Technological University Dublin 
Follow this and additional works at: https://arrow.tudublin.ie/scienmas 
 Part of the Medicine and Health Sciences Commons 
Recommended Citation 
Wynne, C. (2009). Investigation of the P13K/AKT/FOXO and the Ras/Raf/MEK/ERK Signalling Pathways in 
Ovarian Development. Masters dissertation. Technological University Dublin. doi:10.21427/D7SG7T 
This Theses, Masters is brought to you for free and open 
access by the Science at ARROW@TU Dublin. It has been 
accepted for inclusion in Masters by an authorized 
administrator of ARROW@TU Dublin. For more 
information, please contact 
yvonne.desmond@tudublin.ie, arrow.admin@tudublin.ie, 
brian.widdis@tudublin.ie. 
This work is licensed under a Creative Commons 
Attribution-Noncommercial-Share Alike 3.0 License 
INVESTIGATION OF THE PI3K1AKT/FOXO 
AND THE RaslRafIMEKIERK SIGNALLING 
PATHWAYS IN OVARIAN DEVELOPMENT 
Claire M. Wynne BSc 
MPhil Biomedical Science 
June 2009 
School of Biological Sciences, 
Dublin Institute of Technology, 
Kevin Street, 
Dublin 8 
In conjunction with the FAS Science Challenge Internship 
programme at Baylor College of Medicine, Houston, Texas. 
Bay'lor 
COllege 
ofMeillcllle 
ABSTRACT 
The formation and development of ovarian follicles is regulated by the interactions of 
germ cells and somatic cells, intraovarian growth regulatory factors and the pituitary 
gonadotrophins, FSH and LH. Despite the fact that granulosa cells of large follicles are 
highly proliferative, granulosa cell tumours are rare suggesting that potent regulatory 
mechanisms, including apoptotic factors, control proliferation and differentiation of 
these cells. Two critical pathways that intercommunicate to influence ovarian cell 
proliferation and differentiation are the PI3K1AKT/FOXOI pathway and the 
Ras/Raf/MEKIERK cascade. As FSH can stimulate both pathways, a super-ovulatory 
regimen of hormones PMSG/hCG (FSHlLH analogues) administered to immature 
wildtype mice allowed the investigation of key components in these pathways at 
different stages of follicular development. 
In this project cell cycle regulators and apoptotic markers were 
investigated to determine the role they play in ovarian development. Specific PI3K and 
Ras pathway components were studied to decipher how they behaved throughout 
follicular growth. Results indicated that the exact phosphorylation and expression 
pattern of proteins from these pathways happens in a very transient, coordinated and 
timely way. Granulosa cell culture work displayed that extracellular ligands as well as 
FSH have the ability to stimulate both the PI3K pathway and the Ras pathway in quite a 
time-dependent manner. The transcription factor CEBPP is present from once hCG is 
administered to 5 days post hCG treatment suggesting it plays a role at many stages of 
follicular development as well as at the corpora lute a regression stage. 
Some mutant mouse models were investigated to detennine the importance 
of key components in the PI3K pathway and the Ras pathway. This novel insight into 
normal ovarian development suggests that it is the specific time dependent expression 
and cross talk of these pathway components that ultimately results in the coordinated 
and synchronised growth of immature follicles to the corpora lute a stage. 
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1.0 INTRODUCTION 
1.1 The Ovary 
An ovary is an ovum-producing reproductive organ found in female organisms. Ovaries 
are oval shaped, measuring approximately 3cm x 1.5cm x l.5cm in the human. The ovary 
is located in the lateral wall of the pelvis in a region called the ovarian fossa. The fossa 
usually lies beneath the external iliac artery and in front of the ureter and the internal iliac 
artery. Each ovary is attached to the funbre of the fallopian tube. Usually each ovary takes 
turns releasing eggs every month, however if there was a case where one ovary was absent 
or dysfunctional then the other ovary would continue providing eggs to be released. In the 
human the paired ovaries lie within the pelvic cavity, on either side of the uterus, to which 
they are attached via a fibrous cord called the ovarian ligament. There are two extremities 
to the ovary. The end to which the uterine tube attaches is called the tubal extremity. The 
other extremity is called the uterine extremity which points downwards and is attached to 
the uterus via the ovarian ligament. The outermost layer is called the germinal epithelium. 
The tunica albuginea covers the cortex. The ovarian cortex consists of ovarian follicles 
with stroma in between them. Included in the follicles are the cumulus oophorus, 
membrane granulose with granulosa cells inside it, corona radiate, zona pellucida and 
primary oocyte. The zona pellucida, theca of follicle, antrum and liquor folliculi are also 
contained in the follicle. Also in the cortex is the corpus luteum derived from the follicles. 
The innermost layer is the ovarian medulla. It can be hard to distinguish between the 
cortex and medulla, but follicles are usually not found in the medulla. If the egg fails to be 
released from the ovarian follicle an ovarian cyst may form. 
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Figure 1.1: Location of ovaries within the uterus 
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Fig 1.1: Showing where the paired ovaries lie within the pelvic cavity. One on either side of the uterus, to 
which they are attached via the ovarian ligament (http://ovariancancerosw.org/images.ovary.gif) 
1.2 Ovarian Follicular Structure and Development 
The follicle is the basic structural and functional unit of the mammalian ovary. Its major 
function is to produce sexual hormones and support the development of oocytes. According 
to the stages of development, follicles can be classified into primary follicles, secondary 
follicles and antral follicles. A follicle is composed of an oocyte in the centre which is 
surrounded by granulosa cells and theca cells which form the boundary of the follicle. In 
the antral follicle, the granulosa cells further differentiate into the mural granulosa cells, 
which line the antrum and basement membrane and the cumulus cells which are found 
directly adjacent to the oocyte (Fig 1.2b). 
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Figure 1.2a: Cross section of ovary 
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Fig 1.2a: Showing in a clockwise manner, ovarian development from primordial follicle to the antral follicle 
which ovulates the oocyte. Development of the corpus luteum is also shown. The ovary has a rich blood 
supply which spreads out from the medulla of the ovary to the surrounding outer edges. The ovary is attached 
to the uterus by the ovarian ligament. 
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Fig 1.2b: Ovarian Histology 
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Fig J.2b: The image on the left is an ovarian section stained with haematoxylin and eosin. The image on the 
right is a follicle viewed under a scanning electron microscope. According to the stages of development, 
follicles can be classified into primary follicles, secondary follicles and antral follicles. A follicle is composed 
of an oocyte in the centre, surrounded by granulosa cells and theca cells which form the boundary of the 
follicle. In the more mature follicles, outer theca cells are evident. In these follicles the oocyte is surrounded 
by the Cumulus-Oocyte Complex made up of hyaluronic acid and granulosa cell matrix which provides a 
structural support and an optimal communicative/signalling microenvironment for the ovarian cells to 
communicate. 
The development of ovarian follicles involves specific stages: initiation, growth, selection, 
ovulation and luteinisation (Richards JS 1994). At birth the mammalian ovary contains all 
the oocytes which it will produce in a lifetime. These oocytes remain in a quiescent state 
until they are individually stimulated to grow by transcription factors (Richards JS 2001a). 
Pre antral follicles are primordial and primary follicles in which the antrum had not yet 
formed as shown in Fig l.2a. These follicles are classified by the expression of follicle 
stimulating hormone (FSH) receptors on the surface of granulosa cells and the expression 
of luteinising hormone (LH) receptors on theca cells. Selection of the follicle destined to 
ovulate occurs when subtle increases in FSH and LH secretion from the pituitary signals 
the granulosa cells and theca cells to proliferate and ultimately form an antral or 
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preovulatory follicle. Preovulatory follicles are characterised histologically by the 
fonnation of fluid filled space or antrum. The granulosa cells continue to differentiate 
during this stage and begin to express LH receptors in 
addition to P450 aromatase which are responsible for the conversion of androgens from the 
theca cells into estrogens. Increasing amounts of estradiol from the preovulatory follicle 
triggers the pituitary to release surge levels of LH (Downie et al 2005). The LH surge 
induces two key events in the ovary, ovulation and luteinisation. 
1.3 Cumulus-Oocyte-Complex Expansion 
The cumulus-oocyte-complex (COC) is an important micro domain within the follicle. It 
consists of the oocyte and 3-4 surrounding layers of specialised cumulus granulosa cells 
which are separated from the mural granulosa cells by the antrum. Communication 
between the cumulus cells and the oocyte is critical for COC expansion and ovulation to 
occur. This can be demonstrated by the infertility of mice null for the gap junction protein 
connexin 37 which links the oocyte to the adjacent cumulus cells (Salustri A et al 1999). 
cac expansion is initiated by the LH surge and involves the fonnation of a highly complex 
extracellular matrix by cumulus cells. The main structural component of this matrix is the 
glycosaminoglycan hyaluronan. Hyaluronic acid (RA) is a polymer of glucuronic acid and 
N-acdetylglucosamine and can exceed 5000kDa in size (Chen L et al 1990). It has been 
reported that mice null for the prostaglandin synthesis enzyme called cyclo-oxygenase 
enzyme 2 (COX-2) and prostaglandin receptor (EP2) exhibit abnonnal COC expansion 
which is associated with decreased tumour necrosis factor induced gene-6 (TSG-6) mRNA 
levels in cumulus cells, indicating that TSG-6 contributes to the proper fonnation of the 
cumulus-derived extracellular matrix (Mukhopadhyay D et al 2001), (Ochsner SA et af 
5 
2003). Experiments have shown that cac expansion is a critical event which must occur 
for ovulation to proceed (Russell DL et aI2003), (Hizaki H et aI1999), (Kennedy CR et al 
1999). In addition to protecting the oocyte from the proteolytic and mechanical stresses 
during ovulation, the cac matrix has been shown to play a role in fertilisation by 
facilitating egg sperm interactions and the subsequent acrosomal reaction (Chen L et al 
1990), (Hizaki H et aI1999). 
Figure 1.3: Cumulus Oocyte Complex expansion in vitro and in vivo 
LHorhCG 
In vivo 
FSHI AREG/PGE 
In vitro 
Fig 1.3: Cumulus expansion is another unique feature of ovulation in mammals. With the stimulation of LH 
or hCG, the cumulus cells produce large amount of matrix molecules such as hyaluronan. The formation of 
this matrix is critical for successful ovulation and fertilisation. In cultured cumulus-oocyte complexes, 
cumulus expansion can also be induced by adding FSH, amphiregulin or prostaglandin E2 to the media 
(Heng-Yu Fan Richards lab). 
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1.4 The Human Menstrual Cycle 
The sequence of events in the menstrual cycle is determined by the relative hormone levels 
at each stage. The follicular phase of the menstrual cycle spans the first day of 
menstruation until ovulation. The primary goal during the follicular phase is to develop a 
viable follicle capable of undergoing ovulation. The early events of the follicular phase are 
initiated by a rise in FSH levels at the first day of the cycle. The rise in FSH levels can be 
attributed to a decrease in progesterone and estrogen levels at the end of the previous cycle 
and the subsequent removal of inhibition of FSH by these ovarian hormones. FSH 
stimulates the development of 15-20 follicles each month and stimulates follicular secretion 
of estradiol by upregulating secretion of androgens by the theca extema and by inducing 
the aromatase enzyme receptor on granulosa cells. FSH further induces expression of FSH 
receptors on follicles. As estradiol levels increase under the influence of FSH, estradiol 
inhibits the secretion of FSH and FSH levels decrease (JS Richards 2001a). 
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Figure 1.4a: The human menstrual cycle 
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Fig 1.4a: Figure showing gonadotrophin relea ing hOnllOne (GnRH) puLe frequency, gonadotrophic 
hormone level , follicular development tage hormone level , endometrial changes and basal body 
temperatme durillg the follicular and luteal phase or the men lmal cycle. 
FSH functions mainly during follicular growth from the primordial stage to the secondary 
follicle stage. Once the antrum is formed, a LH surge triggers the oocyte to be released. 
This ovulated follicle will then develop into a corpus Juteum and eventually undergo 
apoptosis. 
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Figure l.4b: Hormonal control of folliculogenesis and ovulation 
Granulosa cells 
LH 
surge 
COC 
Oocyte 
Corpus Luteum 
Luteinisation 
Fig lAb: Follicle development in the rodent ovary: Follicles consist of an oocyte surrounded by granulosa 
and theca cells. FSH binds to the FSH receptor on granulosa cells and together with growth factors induces 
proliferation of granulosa and theca cells. LH binds its receptor on granulosa cells of preovulatory follicles to 
induce ovulation and luteinisation. Ovulation is the process by which the cumulus-oocyte-complex (COC) is 
released from the ovary. Luteinisation results in the formation of the corpus luteum, which will eventually 
regress. Some follicles will not develop completely and will instead undergo programmed cell death or 
atresia. 
Under normal circumstances, one follicle evolves into the dominant follicle, destined for 
ovulation, while the remaining follicles undergo atresia. It is cunently not known how the 
dominant follicle is selected, yet it has been observed that the dominant follicle always 
expresses an abundance of FSH receptors (JS Richards 1994). As FSH levels decrease 
towards the end of the follicular phase, the developing follicles must compete for relatively 
small amounts of FSH. The dominant follicle, with its high concentration of FSH 
receptors, continues to acquire more FSH even as FSH levels decrease. The dominant 
follicle can continue to synthesise estradiol, which is essential for its complete maturation. 
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The remaining, poorly FSH receptor-endowed follicles can not produce the requisite 
amount of estradiol. These follicles cease to develop and ultimately undergo atresia. The 
dominant follicle matures and secretes increasing amounts of estrogen. Estrogen levels 
peak towards the end of the follicular phase of the menstrual cycle. At this critical 
moment, estrogen exerts positive feedback on LH, generating a dramatic preovulatory LH 
surge. Estrogen can only exert positive feedback on LH at this precise stage in the 
menstrual cycle, if estrogen is artificially provided earlier in the cycle, ovulation will not be 
induced. The LH surge is required for ovulation. Under the influence of LH, the primary 
oocyte enters the final stage of the first meiotic division and divides into a secondary 
oocyte and the first Barr body. The LH surge induces release of proteolytic enzymes, 
which degrade the cells at the surface of the follicle, and stimulates angiogenesis in the 
follicular wall and prostaglandin secretion. These effects of LH cause the follicle to swell 
and rupture. At ovulation, the oocyte and corona radiata are expelled into the peritoneal 
cavity. The oocyte adheres to the ovary and muscular contractions of the fallopian tube 
bring the oocyte into contact with the tubal epithelium to initiate migration through the 
oviduct. The luteal phase is defined by the luteinisation of the components of the follicle 
which were not ovulated and is initiated by the LH surge. The granulosa cells, theca cells, 
and some surrounding connective tissue are all converted into the corpus luteum, which 
eventually undergoes atresia. The major effects of the LH surge are the conversion of 
granulosa cells from predominantly androgen-converting cells to predominantly 
progesterone-synthesising cells, the expression of new LH receptors which fosters 
increased progesterone synthesis, and reduced affinity of granulosa cells for estrogen and 
FSH. Combined, these changes promote increased progesterone secretion with some 
estrogen secretion. Progesterone secretion by the corpus luteum peaks between five and 
seven days post-ovulation. High progesterone levels exert negative feedback on GnRH and 
subsequently GnRH pulse frequency decreases. As GnRH pulse frequency decreases, FSH 
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and LH secretion also decreases. The corpus luteum further loses its FSH and LH 
receptors. Lacking stimulation by FSH and LH, after 14 days the corpus luteum undergoes 
atresia and begins evolving into the corpus albicans. With the decline of both estrogen and 
progesterone levels, an important negative feedback control on FSH is removed and FSH 
levels rise once again to initiate the next menstrual cycle (Schomberg DW et aI1999). 
1.5 Hypothalamic-Pituitary-Ovary Axis 
The hypothalamus is a region of the brain that controls an immense number of bodily 
functions. It is located in the middle of the base of the brain and encapsulates the ventral 
portion of the third ventricle. The pituitary gland lies immediately beneath the 
hypothalamus, resting in a depression of the base of the skull called the sella turcica 
(http://www.vivo.colostate.edulhbooks/pathphys/endocrine/ hypopit/anatomy.html). In the 
presence of a GnRH pulse, the pituitary and ovarian hormones exert mutual control over 
the circulating levels of one another. This complex interaction between pituitary and 
ovarian hormones involves forward control, positive feed-back, and negative feed-back 
mechanisms which serve to sustain a self-perpetuating monthly endocrine cycle. The levels 
of circulating hormones are regulated by a feed-back mechanism. Increased levels of 
circulating estrogen and progesterone have an inhibitory effect on the hypothalamic 
neurons, which through GnRH decreases the secretion of FSH and LH. 
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Figure 1.5: Negative feed-back control of gonadotrophin secretion from pituitary 
gland 
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Fig 1.5: As estrogen is produced from the granulosa cells a negative feed-back mechanism back to the 
hypothalamus results in a decrease in gonadotrophin secretion. Once progesterone is produced from the 
corpus luteum, a negative feed-back mechanism results in a decrease in gonadotrophin secretion from the 
pituitary gland (http://staff.um.edu.mt/acusllCycIicalChanges.htm) 
1.6 The Rodent Oestrus Cycle 
The normal mouse and rat cycle is 4-5 days, with the ovulatory process requiring 12-14 
hours from the LH surge to the release of the oocyte. Typically oestrus cycles continue 
until death. One difference between the menstrual cycle and the oestrus cycle is that 
animals have the ability to reabsorb the endometruim if conception does not occur during 
that cycle. In rodent ovaries, similar to human ovaries, only one or a few follicles can be 
successfully ovulated in every oestrus cycle. More than 90% of the recruited follicles stop 
growth at various stages of development and are eliminated by apoptosis. This 
phenomenon is called follicle atresia. The pattern of follicular development is highly 
similar in all mammals with the main difference being the rate of growth, the number of 
follicles which are selected and ovulated within each cycle and the cycle length (Richards 
JS et aI1975). 
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The/our phases of the oestrus cycle 
Proestrus 
Oestrus 
One or several follicles of the ovary are starting to grow. Typically this phase 
can last as little as one day or as long as 3 weeks, depending on the species. 
Under the influence of estrogen the endometrium starts to develop. Some 
animals may experience vaginal secretions that could be bloody. The female 
is not yet sexually receptive 
Oestrus refers to the phase when the female is sexually receptive. Under 
regulation by gonadotrophic honnones, ovarian follicles are maturing and 
estrogen secretions exert their biggest influence. The animal exhibits a 
sexually receptive behavior, a situation that may be signalled by visible 
physiologic changes. A signal trait of oestrus is the lordosis reflex, in which 
the animal spontaneously elevates her hindquarters. 
During this phase, the signs of estrogen stimulation subside and the corpus 
Metestrus 
luteum starts to fonn. The uterine lining begins to secrete small amounts of 
Diestrus 
progesterone. This phase typically is brief and may last 1 to 5 days. In some 
animals bleeding may be noted due to declining estrogen levels. 
Diestrus is characterised by the activity of the corpus luteum that produces 
progesterone. In the absence of pregnancy the diestrus phase terminates with 
the regression of the corpus luteum. The lining in the uterus is not shed, but 
will be reorganised for the next cycle. 
Rats typically have rapid cycle times of 4 to 5 days. Although they ovulate spontaneously, 
they do not develop a fully functioning corpus luteum unless they receive coital 
stimulation. Fertile mating leads to pregnancy in this way, but infertile mating leads to a 
state of pseudopregnancy which lasts about 10 days. Mice and hamsters have similar 
behaviour. The events of the cycle are strongly influenced by lighting periodicity. A set of 
follicles start to develop near the end of proestrus and grow at a nearly constant rate until 
the beginning of the subsequent oestrus when the growth rates accelerate eightfold. They 
then ovulate about 109 hours after starting growth. Estrogen peaks at about 11 am on the 
day of proestrus. Between then and midnight there is a surge in progesterone, LH and FSH, 
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and ovulation occurs at about 4am on the next, oestrus day. The following day, metestrus, 
is called early diestrus. During this day the corpora lutea grow to a maximal volume, 
achieved within 24 hours of ovulation. They remain at that size for 3 days, halve in size 
before the metestrus of the next cycle and then shrink abruptly before oestrus of the cycle 
after that. Thus the ovaries of cycling rats contain three different sets of corpora lutea at 
different phases of development. (www.embrology.med.unsw.edu.au/otherEmb/mouse2. 
htm). 
1.7 Gonadotrophins 
Follicle Stimulating Hormone 
FSH is a heterodimer glycoprotein which is comprised of an a- and 13-subunit. The a-
subunit is common to both FSH and LH while the 13-subunit is unique to FSH alone. The 
FSH dimer is synthesised and secreted into the circulation in response to hypothalamic 
GnRH. FSH exerts its effects on granulosa cells by binding to its receptor and initiating 
downstream signalling cascades. The FSH receptor is a seven transmembrane G-protein 
coupled receptor (GPCR). Upon binding ligand the trimeric G protein exchanges 
guanosine 5'-diphosphate (GDP) for guanosine 5'triphosphatee (GTP) causing the Ga 
subunit to dissociate from the G protein complex and bind to the membrane bound effector 
adenylyl cyclase (AC). Activated AC hydrolyses ATP to cAMP to increase intracellular 
cAMP levels. cAMP can in tum activate three classes of intracellular signalling effectors: 
the well characterised cyclic AMP dependent protein, protein kinase A (PKA), cyclic 
nucleotide-gated channels (CNGC), and a class of cAMP-activated guanine nucleotide 
exchange factors (Exchange protein activated by cAMP-EPAC) (Kawasaki H et al 1998), 
(de Rooij Jet alI998), (Richards JS 2001b). 
14 
PKA is the best characterised effector in granulosa cells. PKA is activated 
when cAMP binds to the regulatory subunit of PKA, which causes the dissociation and 
activation of the C subunit. The C subunit may then either phosphorylate cytoplasmic 
substrates or translocate to the nucleus to phosphorylate transcription factors and thereby 
affect gene transcription. FSH primarily effects granulosa cell differentiation by inducing 
the expression of specific genes that promote the growth of the follicle such as aromatase, 
the estrogen receptors (ERa/ERB) (Couse JF et alI990), (Dupont S et al 2000), (Couse JF 
et al1999a), (Couse JF et alI999b), IGF-l, IGF-l receptor (Monget P et aI2000), (Zhou J 
et al 1997) and cyclinD2 (Sicinski P et al 1996). These genes have been extensively 
studied in mutant mouse models lacking the respective genes; all of these models display 
abnormal ovarian phenotypes which underline the importance they play in the gonad. 
Luteinising Hormone 
LH, like FSH is a heterodimeric glycoprotein and shares a common a-subunit with FSH, 
while the I3-subunit is unique to LH. The presence of the LH receptor allows the granulosa 
cells of preovulatory follicles to be responsive to the surge of LH which initiates both 
ovulation and luteinisation. LH binds to its cognate receptor which like the FSH-R is a 
seven pass transmembrane G-protein coupled receptor and primarily activates the PKA 
pathway. LH induces genes necessary for ovulation in a rapid but transient manner. These 
genes include: the rate limiting enzyme in prostaglandin biosynthesis COX-2 (Sirius J et al 
1992a), (Sirius J et al 1992b) and two transcription factors the progesterone receptor (PRJ 
(Lydon JP et al1995) and the CAAT enhancer binding protein beta (CIEBPj3j (Sirios J et al 
1993). Mice null for these genes fail to ovulate, indicating a clear role for these factors in 
the process of ovulation. Other genes and their protein products have been shown to be 
induced by the LH surge include two enzymes which metabolise steroids: prostanoids 
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carbonyl reductase (Espey LL et al2000a) and 3a-hydroxysteroid dehydrogenase (3aHSD) 
(Espey LL et al 2001). 3aHSD is a regulator of G-protein coupled signalling (RGS-2) 
(Ujioka T et al 2000). The cumulus expansion associated gene tumour necrosis factor 
induced gene-6 (TSG-6) (Yoshioka S et al 2000) and the transcription factor early growth 
regulator-l (Egrl) (Espey LL et al2000b) are also induced by the LH surge. Additionally, 
the LH surge initiates cumulus-oocyte-complex expansion as part of the ovulatory program. 
This process involves the production of a highly organised matrix by the cumulus cells. 
While many of the LH-regulated genes listed above (PR, CIEBPfJ. TSG-2 and COX-2) are 
expressed rapidly and transiently after the LH surge (4-8hrs), other genes are induced 
rapidly and sustained over longer periods of time, including Wnt 4 and Fz-4 (Hsich M et al 
2002). Additionally, some LH induced genes are expressed at maximal levels around the 
time of ovulation, such as ADAMTS-l (Espey LL et al2000c), MMP-19 (Hagglund AC et 
al 1999), Fz-l (Hsich M et al 2002) and TIMP-l (Hagglund AC et alI999), and still yet 
others are induced later during luteinisation. 
Luteinisation occurs after the mature oocyte has been ovulated. The LH surge 
terminates follicular growth by down regulating genes that were induced by FSH; i.e. cyclin 
D2, cyclin E (Robker RL et alI998a), aromatase (Fitzpatrick SL et al 1997), LH and FSH 
receptors (Richards JS 1994). Both the mural granulosa cells and theca cells cease to 
divide, undergo hypertrophy, and become highly steroidogenic. Genes induced by LH in 
luteal cells include steriodogenic enzymes, P450scc, StAR (steroidogenic acute regulatory 
protein) (Richards JS 1994), kinases, serum/glucocorticoid induced kinase (Sgk) (Alliston 
TN et al 2000), the cell cycle inhibitor p21Cip and p27Kip (Robker RL et al 1998b), 
transcription factors, Activator protein l(APt) factors Fra2 (Herdegen T et al 1998) and 
JunD (Sharma SC et al 2000), and secreted frizzled related protein (sFRP4) (Hsieh M et al 
2003). All these genes are induced either directly or indirectly by LH and how this occurs 
is not yet understood. 
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How do the FSH and LH receptors work? 
Since the induction of LH-responsive genes does not follow one set pattern, multiple 
mechanisms of LH regulation must exist. One well characterised mechanism of LH-
mediated gene regulation involves a principal target of cAMP dependent phosphorylation 
and activation by PKA, cAMP response element binding protein (CREB). Many LH 
regulated genes contain cAMP response elements (CRE sites) to which CREB binds, 
including aromatase (Carlone DL et al 1997), inhibin a (Pei L et al 1991) and the API 
factors, c-fos (Mukhetjee A et al 1996) and fra2 (Herdegen T et al 1998). Both FSH and 
LH activate similar signalling pathways, so how do they elicit differential responses? One 
theory on how 
FSH receptor and LH receptor mediate differential signals is that they are coupled to 
different cellular signal transducers (Richards JS 1994). There are numerous isoforms of 
adenylyl cyclase (Sunhara et al 1996) which may transduce differential signals. The FSH 
and LH receptors may couple to different isoforms of adenylyl cyclase and therefore 
initiate separate signalling pathways. Carr et al has reported that the difference between 
FSH and LH signalling is not due to differential expression of PKA isoforms in granulosa 
cells (Carr DW et al 1999). Cells of preantral follicles which respond to the LH surge or 
high levels of cAMP express equivalent amounts of the halo enzymes PKAI and PKAII. 
However, they did report a difference in interactions between PKA and A-kinase-anchoring 
proteins (AKAPs) in cells of follicles which respond to FSH and those that primarily 
respond to LH. AKAPs are a family of 25 individual proteins that bind to RII dimers of 
PKAII with nanomolar affinity (Carr DW et al 1999). These complexes are anchored 
through the targeting substrate phosphorylation in a specific location. The differential 
binding of AKAPs to R subunits suggests a redistribution of PKA to a different subcellular 
fraction and therefore possibly the phosphorylation of a specific set of genes. 
17 
Additionally, FSH has been shown to phosphorylate protein kinase B (Akt) 
and Sgk through the activation of the PI3 kinase signalling pathway (Gonzalez-Robayna IJ 
et al 2000). Richards et al propose that the activation of the PI3 kinase pathway by cAMP 
may occur through the activation of cAMP-guanine nucleotide exchange factor (cAMP-
GEF) or exchange proteins activated by cAMP (Epac) (Richards JS 2001b). These proteins 
may actiVate Ras which in turn can activate the PI3 kinase signalling pathway (Pham N et 
al 2000). This mechanism appears to be independent of PKA, suggesting that FSH 
activates alternative signalling pathways. 
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1.8 Steroidogenesis 
Figure 1.8: Production of estradiol from cholesterol 
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Fig 1.8: Showing the production of estradiol from cholesterol and the key enzymes involved in this steroid 
biosyntheti c pathway (www. vivo .colostate. edu/hbooks/pathwayl endocrinelbasicsl steroiogensis/htm). 
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FSH and LH are steroid honnones which are derivatives of cholesterol that are synthesised 
by a variety of tissues, most prominently the adrenal gland and gonads. The cholesterol 
precursor comes from 
cholesterol synthesised within the cell from acetate, from cholesterol ester stores in 
intracellular lipid droplets or from uptake of cholesterol-containing low density 
lipoproteins. Lipoproteins taken up from plasma are most important when steroidogenic 
cells are chronically stimulated. Biosynthesis of steroid honnones requires a battery of 
oxidative enzymes located in both mitochondria and endoplasmic reticulum. The rate-
limiting step in this process is the transport of free cholesterol from the cytoplasm into 
mitochondria. Within mitochondria, cholesterol is converted to pregnenolone by an 
enzyme in the inner membrane called CYPIIA1 (Fig 1.8). Pregnenolone itself is not a 
honnone, but is the immediate precursor for the synthesis of all of the steroid honnones. 
Aromatase serves to convert androgens from the theca cells to estrogen. The importance of 
aromatase to follicular development is illustrated by mice lacking this gene, aromatase 
knock out mice (ARKO). ARKO mice have elevated levels of both LH and FSH and 
folliculogenesis is arrested at the antral stage (Fisher CR et al 1998). Aromatase activity 
increases estrogen which in turn acts via the ERa and EM receptors. Ablation of each ER 
isofonn individually (aERKO and BERKO) as well as together (aBERKO) has revealed 
that both isofonns are important for follicular development and ovulation. aERKO mice 
exhibit increased levels of serum LH which leads to accelerated follicle growth 
(Schomberg DW et al 1999). These mice do not ovulate unless stimulated with exogenous 
honnones (superovulation) at a young age, however they ovulate fewer oocytes and have 
more oocytes that become entrapped in corpora lutea than wild-type mice, indicating an 
important role for ERa in ovulation. While EM is the prominent isofonn in granulosa 
cells (Shanna SC et al 1999), BERKO mice still remain fertile, however their ovulatory 
capacity is reduced from that of wild-type mice (Krege JH et aI1998). aBERKO mice have 
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a much more severe ovarian phenotype than the individual knockout models. These mice 
do not ovulate and have even higher levels of serum LH than the aERKO mice, indicating 
that both isoforms are needed for estradiol-mediated regulation of LH secretion from the 
pituitary. 
Role of Estrogen 
One primary role of estrogen in the ovary is to enhance the effects of FSH by maintaining 
FSH receptor levels (Tonetta SA et al 1989) and inducing the expression of specific genes 
including the LH receptor (Wang XN et aII993), cyclin D2 (Robker RL et al 1998a), the 
transcription factor Forkhead (FOXO), components of the insulin growth factor (lGF-I) 
pathway, IGF-IRJ3 subunit and the glucose transporter Glut-l (Richard JS 2001a). IGF-l 
and its receptor also serve to enhance FSH action in the growing follicle by presumably 
increasing energy utilisation and cell survival in granulosa cells (Richard JS 2001a). 
Cyclin D2 is a cell cycle associated factor that promotes cellular proliferation by positively 
affecting the kinase cascades that regulate transitions through the checkpoints of the cell 
cycle (lnaba T et aI1992). In addition to the regulation of the above genes, the importance 
of FSH to follicular growth is demonstrated by the fact that mice lacking the FSH13 subunit 
of the FSH receptor (Kumar TR et al 1997), (Dierich A et al 1998), (Abel MH Wootton 
AN et al 2000) present with impaired follicular growth at the preantral stage. 
1.9 Cell cycle regulators 
Regulation of the cell cycle within any cell type is complex, involves the balance of many 
regulatory molecules, and can be altered by numerous external signals acting at multiple 
steps in the cycle. In the ovary, estradiol, FSH, and LH are essential signals for the growth 
of preovulatory follicles and their subsequent terminal differentiation as corpora lutea. 
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Each hormone acts via specific receptors and intracellular signalling pathways. 
Additionally, FSH and LH act by controlling distinct levels of cAMP (Jonassen JA et al 
1980). The growth of ovarian follicles, ovulation, and the formation of the corpus luteum 
involves dramatic changes in granulosa cell function. The changes are sequential and are 
dictated by specific, tightly regulated responses to gonadotrophins, steroids, and growth 
factors (Hirshfield AN et al 1991), (Pederson T 1970), (Richards JS 1978). One of the 
most dramatic changes in granulosa cell function is the rapid switch from the highly 
proliferative stage characterising granulosa cells of preovulatory follicles to the 
nonproliferative, terminally differentiated phase of luteal cells. In primordial follicles, the 
oocyte is surrounded by a single layer of nondividing granulosa cells arrested in Go phase 
of the cell cycle. Primordial follicles leave this quiescent state and initiate a phase 
of slow growth in which the granulosa cells have entered the cell cycle but proliferation is 
exceedingly slow (Hirshfield AN et al1991). However, as these slowly dividing granulosa 
cells acquire enhanced responsiveness to FSH and LH and begin producing estradiol, 
exposure to these hormones triggers a rapid burst of proliferation that results in the 
formation of large preovulatory follicles (Rao MC et al 1978). Granulosa cells of these 
preovulatory follicles not only are highly proliferative but are also differentiating and 
acquire LH receptors (Richards JS 1994). The LH surge then triggers dramatic changes in 
both follicular structure and function. LH terminates follicular growth by causing 
granulosa cells of preovulatory follicles to exit the cell cycle (Hirshfield AN et al 1991), 
(Rao MC et al 1978) and rapidly initiates a program of terminal differentiation 
(luteinisation) in which the cells cease to divide (Richards JS 1994). 
This cell cycle progression and proliferation is controlled by a balance of positive 
and negative regulators converging on cell cycle kinase cascades. The pivotal roles of 
Cyclin D2 and p27Kip1 in ovarian follicular growth and differentiation are indicated by their 
selective expression and regulation in the ovary and their critical and opposing effects on 
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cyclin dependent kinase (CDK) activity that controls entry and progression through G 1 of 
the cell cycle. Members of the CDK family playa central role in controlling the normal 
orderly progression of the cell through the division cycle (Fig 1.9). Early in Gl phase, the 
presence of D-type Cyclins activates CDK4 or CDK6. The binding of Cyclin D and 
CDK4/6 results in the formation of a complex that is then phosphorylated by CDK-
activating kinase (CAK). The active Cyclin-CDK complex in turn phosphorylates cellular 
substrates that regulate DNA synthesis. The Cip/Kip family of CDK inhibitors, which 
includes p27KIP1 , acts to block cell cycle progression by binding and inhibiting the activity 
of CDKs. The Cip/Kips (P21 Cipl, p27Kip1 , p57Kip2) have relatively broad specificity and are 
able to bind not only CDK4/6, but also CDK2 and CDC2, enabling them to inhibit the 
activity of several kinase cascades and thereby block cell cycle progression at multiple 
points (Robker RL et al 1998b). 
In the ovary, Cyclin D2 is highly expressed, specifically in granulosa cells, as is 
CDK4 (Rhee K et a11995) while Cyclin Dl and Cyclin D3 are barely detectable (Robker 
RL et a11998a) and mice lacking Cyclin Dl exhibit normal ovarian function (Sicinski P et 
al 1995). In contrast, Cyclin D 1 and Cyclin D3 are expressed in an overlapping pattern, 
with both expressed at the highest levels in theca cells (Robker RL et aI1998a). Cyclin D2 
acts as a positive regulator of cell cycle progression by its ability to bind CDK 4 or 6 and 
thereby activate a cascade of events that permits progression through G 1 phase of the cell 
cycle (Xiong Y et al 1992). In mice null for Cyclin D2, granulosa cell proliferation is 
impaired, the ovarian follicles remain small, and ovulation fails to occur (Sicinski P et al 
1996). In contrast, p27Kipl blocks cell cycle progression by inactivating these same CDK 
cascades, and cells remain in Gl phase (Polyak K et al 1994). Both p27Kipi and a related 
family member, p21 Cipl, are highly expressed in the corpus luteum with only slightly 
different patterns of induction (Robker RL et al 1998a). However, they appear to play 
unique roles in this tissue. Mice lacking p27Kipi exhibit an altered ovarian phenotype, 
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follicular growth is not compromised but granulosa cells do not luteinise properly in 
response to LH (Nakayama K et aI1996), (Kiyokawa H et al 1996), (F ero ML et al 1996). 
Figure 1.9 CDK Inhibition during the cell cycle 
Inhjbition 
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InhibItion 
Fig 1.9: CDK can inhibit at various stages of the cell cycle (http://www.cancerline.com/CancerLineHCP/ 
15602_18505_9_5_ O.aspx) 
Many cancers exhibit at least one alteration in the complex mechanisms controlling CDK 
activity, such as over-expression of Cyclins or loss of CDK inhibitor expression, which can 
lead to uncontrolled cell division. Therefore targeting CDKs in tumour cells offers an 
attractive therapeutic approach for a wide range of tumour types. 
In order to better understand the control of cellular proliferation in the ovary, we 
analysed the expression of these cell cycle regulatory molecules and their regulation by 
hormones during follicular development, specifically when granulosa cell proliferation is 
rapid and during luteinisation when cell division has terminated. The results presented 
highlight the ability of the LH surge to acutely regulate Cyclin D2 and p27Kipi in an inverse 
manner. 
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1.10 Study Design 
Mice were used for westem blot procedures usmg whole ovary lysates, 
immunofloursescence staining and immunohistochemistry staining. Rats were used for 
granulosa cell isolation and cell culture work. (Note: In the case of figure 4.13 mice 
granulosa cells were cultured to use for the longer hCG series for comparison purposes 
with the mouse hCG series in figure 4.12. Also in figure 4.17 demonstrating a comparison 
of wild type ovary with Pten CKO ovary, granulosa cells were isolated). 
Figure 1.10: Study Design showing how mice and rat ovaries were treated 
[ Mice work 1 
Mice were injected with 
PMSG and 48 hours later 
with heG at 2, 4, 8, 12 and 
16 hour time points. A 
non-treated (NT) mouse 
was used as a negative 
Sacrificing mice after various 
stages of hCG treatment 
allowed the investigation of key 
pathway components at specific 
stages of follicular development 
Western Blot: 
Ovaries were 
removed, lysed, 
sonicated and 
quantified by 
Bradford assay. 5 
ovaries were 
pooled and used 
for each time point 
Immunofluorescence 
staining: Ovaries 
were snap frozen 
once removed. 
Haematoxylin and 
Eosin staining: 
Ovaries were 
paraffin wax 
embedded once 
removed 
[ Ratwork 1 
Rats were injected with estradiol 
for 3 consecutive davs 
Ovaries were now at the 
preovulatory stage and so 
allowed us to investigate key 
pathway components in 
immature granulosa cells 
Rats were sacrified 
and ovaries removed. 
Granulosa cells were 
isolated from rat 
ovaries by poking the 
ovaries using syringes 
Granulosa cells were 
cultured overnight and 
treated with various ligands. 
Cells were then lysed and 
used for western blot 
analysis/mRNA extraction 
1.11 Cell Signalling Pathways in the Ovary 
The epidermal growth factor receptor (EGFR) family plays an important role in cell lineage 
determination, the morphogenesis of many organs and in cell survival in the adult (Yarden 
2001, Jorrissen et ai, 2003; Nair 2005, Henson and Gibson 2006). Moreover, activating 
mutants and over-expression of these family members contribute to oncogenesis by 
inducing cells to proliferate and to resist apoptosis. ErbB3, a member of the EGFR family, 
has an inactive kinase domain therefore these receptors are thought to serve as co-receptors. 
Amphiregulin is a ligand for the ErbB family which binds to EGFR. Upon ligand-binding, 
receptors homo-dimerise or hetero-dimerise triggering tyrosine trans-phosphorylation of 
the receptor sub-units. Intracellular tyrosine kinases of the Src family and Abl family are 
also able to tyrosine phosphorylate ErbB receptors. These tyrosine phosphorylated sites 
allow proteins to bind through their Src homology 2 (SH2) domains leading to the 
activation of downstream signalling cascades including the RAS/extracellular signal 
regulated kinase (ERK) pathway, the PI3K pathway and the JAKISTAT pathway. 
Differences in the C-terminal domains of the ErbB receptors govern the exact second 
messenger cascades that are elicited conferring signalling specificity. The EGF signal is 
terminated primarily through endocytosis of the receptor-ligand complex. The contents of 
the endosomes are then either degraded or recycled to the cell surface. 
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Figure 1.11: An overview of signalling pathways investigated in this study 
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Fig 1.11: Once FSHlLH binds its 7 -transmembrane G-protein coupled receptor the main pathway activated is 
the PKA pathway. FSHJLH binding can also induce the activation of the JAK/STAT pathway and the 
Ras/Raf/MEKlERK pathway through EGFR receptor activation. It is though that once FSHlLH binds its 
receptor, Ras is activated and binds and activates the EGF receptor. Activation of the EGF receptor results in 
autophosphorylation of key tyrosine residues. These tyrosine phosphorylated sites allow proteins to bind 
through their Src homology 2 (SH2) domains and leads to the activation of downstream signalling cascades. 
Ras can also bind the IGF receptor resulting in PI3K activation and the resulting activation of the 
PI3K1AKTIFOXO pathway. These pathways act in a coordinated manner to promote cell survival. 
1.11 (i) PI3 kinase pathway 
Epidennal Growth Factor (EGF) promotes cell survival through the activation of PI3K 
signalling (Henson and Gibson 2006). PI3K are a family of related enzymes that are 
capable of phosphorylating the 3 position hydroxyl group of the inositol ring of 
phosphatidylinositol. EGF triggers the recruitment of PI3K to activated ErbB receptors, 
which is mediated by the binding of SH2 domains in PI3K to phosphorylated tyrosine 
residues. The catalytic subunit of PI3K in tum phosphorylates phosphatidylinositol (4,5) 
bisphosphate (PIP2) leading to the fonnation of phosphatidylinositol (3,4,5) triphosphate 
(PIP3). The PI3K family is composed of Class I, II and III, with Class I kinases being the 
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only type with the ability to convert P1P2 to P1P3 on the inner leaflet of the plasma 
membrane. PI3K can also activate ras (rat sarcoma homologue gene), resulting in the 
activation of ERK signalling, thereby facilitating cross-talk between survival pathways. A 
key downstream effector of PIP3 is Protein Kinase B (AKT). AKT requires the formation 
of the PIP3 molecule in order to be translocated to the cell membrane. AKT promotes cell 
survival through the transcription of anti-apoptotic proteins. A downstream target of AKT 
is glycogen synthase kinase 3 (GSK3). Under basal conditions the constitutive activity of 
GSK3 leads to the phosphorylation and inhibition of a guanine nucleotide exchange factor 
eIF2B, which regulates the initiation of protein translation. Therefore, upon inactivation of 
GSK3 by AKT, eIF2B is dephosphorylated resulting in the promotion of protein synthesis 
and the storage of amino acids (Lizcano and Alessi 2002). AKT also activates mammalian 
target of rapamycin (mTOR), which promotes protein synthesis through p70 ribosomal S6 
kinase (P70s6k) and inhibition of eIF-4E binding protein (4E-BPl) (Asnaghi et at 2004). 
Collectively, these processes all promote cell growth and survival in response to EGF. 
FSH can activate the PI3K pathway by associating with its G-protein 
coupled receptor (FSHR) which binds the p85 subunit of PI3K and activates the pllO 
catalytic subunit of PI3K. This mediates the phosphorylation of PIP3, a key signalling 
intermediate that recruits and activates downstream molecules. AKT (originally identified 
as the oncogene in the transforming retrovirus, AKT8 by Dr. Philip TSichlis at Fox Chase 
Cancer Centre in the 1990's) is one key downstream target ofPI3K, activated by serine and 
threonine phosphorylation. AKT possesses a protein domain known as Pleckstrin 
Homology (PH) domain, named after Pleckstrin, the protein in which it was first 
discovered. This domain binds to PIP2 or PIP3 with high affInity. Once correctly 
positioned in the membrane via binding of P1P3, AKT can then be phosphorylated by its 
activating kinases, phosphoinositide dependent kinase 1 (PDKI at threonine 308) and 
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mTORC2 (mammalian target of rapamycin complex 2) at serine 473. Phosphorylation of 
mTORC2 stimulates the subsequent phosphorylation of AKT by PDK1. Activated AKT 
can then go on to activate or deactivate its myriad substrates via its kinase activity. In 
addition to AKT and PDKl, one other related serine threonine kinase is bound at the PIP3 
molecule created as a result of PI3K activity, SGK. SGK and AKT can phosphorylate the 
forkhead transcription factor 1 (FOXO 1) rendering it inactive and excluding it from the 
nucleus (Fig 1. 11 (i)). FOXO factors impact a diverse number of cellular processes 
including apoptosis, cell cycle progression, DNA repair, responses to oxidative stress as 
well as longevity. Recent studies indicate that these diverse effects of FOXOI may be 
regulated by a diverse set of kinases that phosphorylate specific residues in the FOXO 
molecule. For example, FOXOI can be phosphorylated by kinases that are linked to cell 
cycle progression (CDK2), oxidative stress (AMPK) and apoptosis (MSTI and JNK). 
Interestingly phosphorylation of FOXO 1 by CDK2 promotes nuclear exclusion whereas 
phosphorylation by stress-related kinases promotes nuclear retention and presumably 
increased transcriptional activity of FOXO factors (Huang et al 2006). Thus the cellular 
localisation of FOXO factors is regulated by more complex mechanisms than originally 
thought. p27Kip has been identified as a FOXO 1 regulated gene in liver endothelial cells. 
FOXO factors appear to work in a cell context specific manner. In general, growth factors 
activate the PI3K1AKT pathway leading to FOXO phoshorylation and inactivation and 
often cell differentiation (Stahl et aI2002). 
Apart from being a downstream effector of PI3K, AKT may also be 
activated in a PI3K-independent manner. Studies have suggested than cAMP-elevating 
agents could activate AKT through protein kinase A (PKA) , although the mechanism of 
action is unclear. PI3K dependent AKT activation can be regulated through the tumour 
suppressor phosphate and tensin homologue (PTEN) which works essentially as the 
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opposite ofPI3K. PTEN acts as a phosphatase to dephosphorylate PIP3 back to PIP2. This 
removes the membrane-localisation factor from the AKT signalling pathway. Without this 
localisation, the rate of AKT activation decreases significantly, as do all the downstream 
pathways that depend on AKT for activation. PTEN is absent in many tumours, hence 
PI3K activity contributes significantly to cellular transformation and the development of 
cancer. 
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Figure 1.11 (i): FSH regulation ofthe PI3K1AKTIFOXO pathway in granulosa cells 
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1------- PTEN 
Fig 1.11 (i): This diagram shows how the balance of proliferation, apoptosis and differentiation is maintained 
within granulosa cells. FSH binds and activates its receptor FSHR. PI3K is activated through SRC/ABLl. 
PI3K can then result in activation of the PDKlIAKT/p70S6k pathway or the 
PDK2/AKTIFOXOl(PDK2/SGKlFOXOl) pathway. When phosphorylated by AKT/SGK, FOXO factors can 
be excluded from the nucleus and rendered inactive. PI3K can be inhibited by PTEN. Stress induced MSTl 
and JNK are thought to playa part in targeting FOX01 from the cytoplasm to the nucleus . p27KIP 
phosphorylation can affect both cytoplasmic FOXOl and nuclear FOXO 1. 
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1.11 (ii) RaslRaflMEKIERK pathway 
Mitogen-activated protein kinase (MAPK) pathways are major signal transduction routes 
that transfer and amplify messages from the cell surface to the nucleus, producing a range 
of cellular effects, eg cell proliferation. There are several distinct MAPK pathways 
important in the regulation of cell proliferation, differentiation, development, inflammation, 
survival, and migration. One of these pathways, the Ras-Raf-MEK-ERK pathway (Fig 
1.11 (ii)) is activated by a range of growth factor receptors including EGFR, platelet derived 
growth factor receptor, type-l insulin-like growth factor receptor, and fibroblast growth 
factor receptor. The pathway can also be activated by cytokines, hormones such as FSH 
and several agonists that act via G-protein-coupled receptors. Receptor-linked tyrosine 
kinases such as the EGFR are activated by extracellular ligands. Binding of epidermal 
growth factor (EGF) to the EGFR activates the tyrosine kinase activity of the cytoplasmic 
domain of the receptor. The EGFR becomes phosphorylated on tyrosines. Docking 
proteins such as GRB2 contain SH2 domains that bind to the phosphotyrosines of the 
activated receptor. GRB2 binds to the guanine nucleotide exchange factor, Son Of 
Sevenless (SOS), by way of an Src homology 3 (SH3) domain of growth factor receptor 
bound protein 2 (GRB2). When the GRB2-S0S complex docks to phosphorylated EGFR, 
SOS becomes activated. Activated SOS promotes the removal of GDP from rat sarcoma 
homologue (Ras). 
Ras is an oncogene product that is found on chromosome 11. It is found in 
normal cells, where it helps to relay signals by acting as a switch 
(http://www.ncbi.nlm.nih.govlbooks/ bv .fcgi?call=bv. View .ShowSection&rid=gnd). Ras is 
a G protein, specifically a small GTPase. Ras serves as a binary molecular switch and its 
bioactivity is controlled by a regulated GDP/GTP cycle (Campbell SL et al 1998). Ras 
cycles between two conformations, an activated or inactivated form, respectively RAS-
GTP and RAS-GDP. When receptors on the cell surface are stimulated (by FSH for 
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example), Ras is switched on and transduces signals that tell the cell to grow. If the cell-
surface receptor is not stimulated, Ras is not activated and so the ERK pathway is not 
initiated. In about 30% of human cancers, Ras is mutated so that it is permanently switched 
on, telling the cell to grow regardless of whether receptors on the cell surface are activated 
or not. Ras can then bind GTP and become active. (Henson and Gibson 2006). SOS then 
activates RAS leading to the activation of RAF-l. RAF-l subsequently phosphorylates 
MAPKIERK kinase I (MEKl) and MAPKIERK kinase 2 (MEK2) which activate ERKI 
and ERK2 respectively. MEK1I2 is a dual-specificity kinase that is essential to the 
propagation of growth factor signalling and is known to amplify signals to ERK1I2, also 
known as MAPK1I2, that in tum can phosphorylate and activate a range of proteins, 
including several transcription factors (Campbell et al 1998). MAPK regulates the 
activities of several transcription factors. MAPK can phosphorylate C-myc. MAPK 
phosphorylates and activates MNK which in tum phosphorylates CREB. MAPK also 
regulates the transcription of the Fos gene. By altering the levels and activities of 
transcription factors, MAPK leads to altered transcription of genes that are important for 
the cell cycle (Johnson et aI200l). 
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Figure 1.11 (ii): The Ras-Raf-MEK-ERK signalling pathway 
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Fig 1.11 (ii): In the case of granulosa cells FSH binds its G-protein coupled receptor and activates the 
membrane bound GTPase Ras. Ras then activates Raf when subsequently phosphorylates MEKl/2. 
Activation ofERKl/2 follows which results in cell proliferation, differentiation and survival. 
Constitutive activation of the Ras-Raf-MEK-ERK pathway has been demonstrated In 
several cancer types, pancreas (90%), colon (50%), lung (30%), thyroid (50%), bladder 
(6%), ovanan (15%), breast, skin, liver, kidney, and some leukemias 
(http://www .cancerquest.orglindex.cfm ?page=553). Inhibition of this pathway via 
MEKl/2 is an attractive strategy for therapeutic intervention in cancer because it has the 
potential to block inappropriate signal transduction regardless of the upstream position of 
the oncogenic aberration. Furthermore, ERK1I2 are the only known substrates for 
MEKl/2. This pathway results in cell proliferation and in the increased transcription of 
Bc1-2 family members and inhibitor of apoptosis proteins (lAPs), thereby promoting cell 
survival (Saltiel & Kahn 2002, Saltiel & Pessin 2002). The ERKs are proline-directed 
protein kinases, phosphorylating pro-neighbouring serine or threonine residues. Docking 
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sites present on physiological substrates confer additional specificity. These docking 
interactions, through non-catalytic regions on ERK, team with scaffolding proteins to 
ensure signalling fidelity and enzymatic efficiency both to and from the MAPK. 
Downstream, activated ERK regulates growth factor-responsive targets in the cytosol and 
also translocates to the nucleus where it phosphorylates a number of transcription factors 
regulating gene expression. In this project a mouse model is generated to investigate the 
effects of constitutively active Ras on granulosa cell development. Constitutively active 
Ras is achieved by a mutation that prevents GTP hydrolysis, thus locking Ras in a 
permanently 'On' state 
1.11 (iii) JAKISTAT pathway 
Another signalling cascade initiated by EGF is the Janus kinase/Signal Transducers and 
Activators of Transcription (JAK/STAT) pathway which is also implicated in cell survival 
responses (Henson and Gibson 2006). JAK phosphorylates STAT proteins localised at the 
plasma membrane. This leads to the translocation of STAT proteins to the nucleus where 
they activate the transcription of genes associated with cell survival. 
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Figure 1.11 (iii): The JAKISTAT pathway 
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Fig 1.11 (iii): The JAKISTAT pathway can be activated in the same manner as the PI3K pathway shown on 
the left and the ERK pathway shown on the right of this diagram 
(http://www.signalwayantibody.com/resurgam/p _img/Jak _ Stat]athway.git) 
STATs were originally discovered as targets of Janus Kinases, it has now become apparent 
that certain stimuli can activate them independently of JAKs. The pathway plays a central 
role in principal cell fate decisions, regulating the processes of cell proliferation, 
differentiation and apoptosis. JAKs, which have tyrosine kinase activity, bind to some cell 
surface cytokine receptors (Fig 1.11 (iii)). The binding of the ligand to the receptor triggers 
activation of JAKs. With increased kinase activity, they phosphorylate tyrosine residues on 
the receptor and create sites for interaction with proteins that contain phosphotyrosine-
binding SH2 domain. ST A Ts possessing SH2 domains capable of binding these 
phosphotyrosine residues are recruited to the receptors, and are themselves tyrosine-
phosphorylated by JAKs. These phosphotyrosines then act as docking sites for SH2-
domains of other ST A Ts, mediating their dimerisation. Different ST A Ts form hetero- as 
well as homodimers. Activated STAT dimers accumulate in the cell nucleus and activate 
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transcription of their target genes. STATs may also be tyrosine-phosphorylated directly by 
receptor tyrosine kinases, such as the EGFR as well as by non-receptor tyrosine kinases, 
such as c-src. Stat 5 is of particular interest within the ovary. Stat 5 has previously been 
identified as a transcription factor activated by prolactin in the mammary gland 
(Hennighausen et al 2001). Prolactin acts in the ovary to promote the maintenance and 
function of the corpus luteum. However, the cellular signals that induce these responses 
have not yet been clearly defmed. Stat 5 is also activated by prolactin in the ovaries of 
pseudopregnant rats (Teglund et al 1998). Intraperitoneal injection of prolactin into 
pseudopregnant rats results in the tyrosine phosphorylation and nuclear translocation of Stat 
5. This activated Stat 5 possesses DNA-binding activity for a sequence containing the 
Prolactin-inducible element. It has also been reported that luteinisation of PMSG primed 
ovaries by the administration of hCG is accompanied by an induction of Stat 5 protein 
(Ruff et al 1996). For this reason, some cell culture work was carried out using PMSG 
primed, hCG treated ovaries to investigate if cells which have been treated with 
extracellular ligands such as Amphiregulin, IL6 and FSH can result in the induction of Stat 
5 protein. 
The JAKIST AT pathway is negatively regulated on multiple levels. Protein 
tyrosine phosphatases remove phosphates from cytokine receptors as well as activated 
STATs. More recently identified Suppressors of Cytokines Signalling (SaCS) inhibit 
STAT phosphorylation by binding and inhibiting JAKs or competing with STATs for 
phosphotyrosine binding sites on cytokine receptors. ST ATs are also negatively regulated 
by Protein Inhibitors of Activated STATs (PIAS), which act in the nucleus through several 
mechanisms. For example, PIAS1 and PIAS3 inhibit transcriptional activation by STAT! 
and STAT3 respectively by binding and blocking access to the DNA sequences they 
recognise (Ke Shuai 2006). 
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1.12 CEBP/8 
A large number of intercellular signalling molecules have been identified that orchestrate 
female reproductive physiology. However, with the exception of steroid hormone 
receptors, little information exists about the transcriptional regulators that mediate cellular 
responses to these signals. The transcription factor C/EBPB (CCAAT/enhancer-binding 
protein beta) is expressed in ovaries and testes, as well as many other tissues of adult mice. 
C/EBPB is a member of a family of basic helix-loop-helix transcription factors. Mice 
carrying a targeted deletion of the C/EBPB gene exhibit reproductive defects. Although 
these animals develop normally and males are fertile, adult females are sterile. C/EBP-
deficient ovaries lack corpora lutea and fail to down-regulate expression of the 
prostaglandin endoperoxidase synthase 2 and P450 aromatase genes in response to 
gonadotrophins. These findings demonstrate that C/EBPB is essential for peri ovulatory 
granulosa cell differentiation in response to LH (Sirios et at 1993). Transplantation of 
normal ovaries into mutant females restored fertility, thus localising the primary 
reproductive defect to the ovary proper. C/EBPB is thus established as a critical 
downstream target of G-protein-coupled LH receptor signalling and one of the first 
transcription factors, other than steroid hormone receptors, known to be required for 
ovarian follicle development in vivo (Stemeck et al 1997). In normal ovaries, C/EBPB 
mRNA is specifically induced by luteinising hormone (LH/hCG) in the granulosa layer of 
preovulatory antral follicles. FSH also induces CIEBPB (Pall et al 1997). In this project a 
PMSG primed hCG ovarian series was studied to investigate the time point C/EBPB is 
induced. Some cell culture work was also carried out to determine if ligands such as 
Amphiregulin and FSH increase C/EBPB expression in vitro. 
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1.13 Apoptotic Markers: MST1 and SAPKlJNK 
Mammalian Ste20-like kinase (Mstl) and stress-activated protein kinase/Jun-amino-
terminal kinase (SAPKlJNK) are members of the germinal centre kinase family and are 
thought to be activated and translocated from the cytosol to the nucleus by apoptotic signals 
as well as other stress conditions. It is thought that activated MST kinases may rely on 
p38MAPK and JNK pathways to amplify apoptotic signals (Lee, K et al 2001). MSTI is 
an upstream kinase of the JNK and p38 MAPK pathways whose expression induces 
apoptotic morphological changes such as nuclear condensation. During apoptosis, caspase 
cleavage of MSTI removes a C-terminal regulatory domain, increasing the kinase activity 
of the MSTI N-terminal domain. Downstream pathways of MSTI in the induction of 
apoptosis remain to be clarified (S Ura et al 2001). SAPKlJNK is potentially and 
preferentially activated by a variety of environmental stresses, including UV and gamma 
radiation, ceramides, inflammatory cytokines and in some instances by growth factors. 
Stress signals are delivered to the cascade by small GTPases of the Rho family. 
SAPKlJNK, when active as a dimer can translocate to the nucleus where it regulates 
transcription through its effects on c-Jun, ATF-2 and other transcription factors (Kyriakis et 
al 2001). The MEKKI protein kinase is a proximate activator of the SAPKlJNK stress-
signalling pathway. A variety of environmental stresses, including inflammatory cytokines, 
hyperosmotic shock, and UV light stimulate the cascade (Yan et al 1994). MEKKI is 
implicated in apoptotic cell death, but surprisingly MEKKI activates nuclear factor kappa 
B (NFkB) pathways that induce expression of genes to counteract the apoptotic death 
response (Cross et alI999). 
MSTI and JNK can be activated by oxidative stress. This stress 
results in the phosphorylation of FOXO 1 at a conserved site within the forkhead domain 
that promotes FOXO nuclear translocation. This translocation induces cell death (Lehtinen 
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et al 2006) (Fig 1. 11 (i)). It has been shown that transgenic mouse line expresses a 
constitutively active p 11 O-alpha subunit in the epithelial cells of the prostate results in an 
elevated level ofMSTI. This elevation and the phosphorylation of AKT could be inhibited 
in vivo in transgenic animals by the PI3K inhibitor L Y294002 (Renner et al 2007). MSTI 
is therefore a marker for PI3K activity. To investigate the roles MSTI and SAPKlJNK 
play in ovarian development and to study how they relate to FOXOI expression, 
immunofluorescence staining was carried out on ovarian sections for both MSTI and 
pSAPKlJNK and an heG series was also examined for MSTl, pSAPKlJNK and FOXOI 
protein expression. 
1.14 Extracellular ligands 
1.14 (i) Interleukin 6 
Interleukin 6 (IL6), a broad spectrum cytokine, has previously been demonstrated to be 
produced by granulosa cells and to directly influence FSH differentiated functions of 
ovarian granulosa cells (Van der Hoek et aI1998). IL6, a B cell differentiation factor, has 
been shown to exert modulatory influence over ovarian function. IL6 is capable of directly 
influencing FSH-stimulated progesterone production by granulosa cells in vitro. Moreover, 
IL6 is produced by the granulosa cell, suggesting a potential role for this cytokine in the 
autocrine and/or paracrine regulation of ovarian function. IL6 secretion by granulosa cells 
is an event that may be regulated by a number of cytokines as well as FSH (Van der Hoek 
et al 1998). FSH has been shown to cause significant concentration-dependent increases in 
IL6 release in granulosa cell release suggesting granulosa cells are a likely source of IL6. 
cAMP may serve as a second messenger for the stimulated secretion of IL6 by 
undifferentiated granulosa cells (Gorospe et al 1993). As IL6 interacts with its receptor, it 
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triggers the gp130 and IL-6R proteins to fonn a complex, thus activating the receptor. 
These complexes bring together the intracellular regions of gp130 to initiate a signal 
transduction cascade through the transcription factors JAKs and STATs. IL6 is probably 
the best studied of the cytokines that use gp 130 in their signalling complexes. In addition 
to the membrane-bound receptor, a soluble fonn of IL-6R has been purified from human 
serum and urine. Previous studies indicate that the pleiotropic cytokine IL6 may contribute 
to the vascularisation of some tumours by disrupting the equilibrium between positive and 
negative angiogenic regulatory molecules. Human ovarian carcinoma cell lines have been 
shown to secrete significant levels of the soluble IL6 receptor and elevated serum levels of 
IL6 has shown to be associated with poor patient survival (Nilsson et al 2005). The 
molecular mechanism(s) by which IL6 can regulate angiogenesis still however remain 
unclear. Nilsson et al also showed that the addition of IL6 to cultured endothelial cells of 
the ovary resulted in a significant increase in cell proliferation suggesting that IL6 secreted 
by ovarian cancer cells can be an endothelial cell mitogen. Recently this group has also 
shown that stress honnones such as norepinephrine lead to increased expression of IL6 
mRNA and protein levels in ovarian carcinoma cells. They also demonstrate that 
norepinephrine stimulation activates Src tyrosine kinase, and this activation is required for 
increased IL6 expression (Nilsson et aI2007). To test if this ligand has the ability to effect 
the PI3K1AKT/FOXO and the Ras/RafIMEKiERK signalling pathways in ovarian 
development, granulosa cells were isolated from rat ovaries and treated with IL6 to 
determine if levels of key components in both these signalling pathways were altered. 
1.14 (ii) Amphiregulin 
Amphiregulin (ARE G) was originally isolated from the conditioned medium of a human 
breast carcinoma cell line MCF-7 (Shoyab et al. 1988). AREG is a member of the EGF 
family of proteins. AREG binds to the EGF receptor but not as well as EGF does. AREG 
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is induced in the rat ovary by gonadotrophin treatment. LH activates a cascade of 
signalling events that are propagated throughout the ovarian preovulatory follicle to 
promote ovulation of a mature egg. Critical to LH-induced ovulation is the induction of 
EGF-like growth factors and transactivation ofEGF receptor signalling. The expression of 
AREG mRNA is inducecd in PMSG treated rats after 24 hours but the expression then 
decreases 48 hours after treatment. Further treatment with hCG rapidly induces the 
expression of AREG genes showing maximal levels 4 hours after hCG treatment 
(Sekiguchi et al 2004). To investigate if AREG influences downstream components of the 
PI3K1AKT/FOXO and the Ras/Raf/MEKIERK signalling pathways in pre-antral follicles, 
granulosa cells were isolated from estradiol injected rat ovaries and treated with this ligand. 
1.14 (iii) Forskolin 
Forskolin is the main active ingredient in the Ayurvedic herb Coleus forskohlii. Coleus is a 
member of the mint family and grows in subtropical areas in India, Burma, and Thailand. 
Forskolin is commonly used to raise levels of cyclin AMP (cAMP) in the study and 
research of cell physiology. Forskolin resensitises cell receptors by activating the enzyme 
adenylyl cyclase and increasing the intracellular levels of cAMP (Godard et al 2005). 
cAMP appears to have additional actions that are due to its ability to alter a number of 
membrane transport proteins. cAMP and the chemicals it activates comprise a second 
messenger system that is responsible for carrying out the complex and powerful effects of 
hormones in the body. It is required for cell communication in the hypothalamus/pituitary 
gland axis and for the feed-back control of hormones. It acts by activating protein kinase A 
(Hedin et al1983). Forskolin has been extensively researched in the medical field for use 
in the treatment of allergies, respiratory problems, cardiovascular diseases, glaucoma, 
psoriasis, hypothyroidism, and weight loss. The effects of forskolin on IL6 release by 
granulosa cells have been examined. The results showed a significant concentration-
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dependent increase in IL6 production by granulosa cells in either the absence or presence of 
FSH (Gorospe et at 1993). It has previously been. demonstrated that ovulated oocytes 
treated with LH or forskolin resume meiosis showing that an increase in ovarian cAMP, 
even if not induced by LH, is sufficient to cause ovulation of preovulatory rat follicles, 
supporting the involvement of cAMP in the normal ovulatory process (Brannstrom et at 
1983). The binding of LH to its receptors in the ovary activates adenylate cyclase in the 
cell membrane, which in tum results in an increase in intracellular cAMP levels. It is also a 
well-documented fact that cAMP acts as a second messenger for LH in the stimulation of 
steroidogenesis. For these reasons, granulosa cells from estradiol-treated rats were cultured 
overnight and treated with forskolin to investigate the effects forskolin treatment has on 
PI3K pathway and ERK pathway components. 
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1.15 Mouse Strains 
Pten conditional knock out mouse model 
PTEN is the negative regulator of the PI3K pathway. In order to investigate the effect of a 
hyperactive PI3K1AKT/FOXO cascade on ovarian cell function a conditional Pten knock 
out mouse strain was generated. This was done by mating Pterl'lfl mice with transgenic 
mice expressing CRE recombinase driven by the CypJ9 (aromatase) promoter. This 
resulted in Pten mRNA and protein being specifically disrupted/reduced in granulosa cells 
(but not other cells) of growing follicles of the mutant. 
LSL-K-rasG12D-Amhr2-Cre conditional knock-in mouse model 
The small G-protein RAS is critical for FSH-induced signalling events in cultured 
granulosa cells, but the functions of RAS in granulosa cells during follicular development 
have not been defined. Therefore, to determine the impact of RAS activation on granulosa 
cells in vivo, a conditional knock-in mouse model in which granulosa cells expressed a 
constitutively active K_rasG12D was generated, driven by the Anti- Mullerian hormone 
receptor-2 (Amhr-2) promoter. In the (LSL) Lox-Stop-Lox-K-rasG12D-Amhr2-Cre model, 
Ras was engineered to be constitutively active in granulosa cells. Constitutively active Ras 
is one which contains mutations that prevent GTP hydrolysis, thus locking Ras in a 
permanently 'On' state. assay (Soriano P, 1999). These mice displayed a subfertile 
phenotype with oocytes trapped in corpora lutea 48 hours post hCG injection. 
Note: Genotyping as described in Section 3.11 was carried out on both the Pten conditional 
knock out mouse model and the LSL-K-rasG12D-Amhr2-Cre conditional knock-in mouse 
model. Immature wild type C57BLl6 mice were also used. 
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2.0 AIMS 
The PI3K1AKT/FOXO and Ras/Raf/MEKlERK cascades are known vital pathways for 
sustaining the balance between proliferation, differentiation, cell survival and apoptosis and 
as a consequence of this affecting folliculogenesis, ovulation and luteinisation. 
Considering this, the primary aims of this project were: 
1. To study the role that cell cycle regulators Cyclin D2 and p27K1P play in ovarian cell 
proliferation and differentiation and to investigate the significance of two apoptotic 
markers MSTI and p-SAPKlJNK in follicle atresia. 
2. To study the phosphorylation pattern of some downstream targets in the 
PI3K1AKT/FOXO pathway and to assess whether extracellular ligands such as 
Amphiregulin and Interleukin-6 displayed the ability to induce phosphorylation of a 
key intermediate in the pathway, AKT. 
3. To elucidate the role CIEBP ~ plays in ovarian folliculogenesis and ovulation and to 
determine the effects Follicle Stimulating Hormone and Amphiregulin have on 
C/EBP ~ action. 
4. To compare ovarian morphology between wildtype mice and a genetically 
engineered Pten conditional knock out mouse strain, so as to determine the 
importance of PTEN in maintaining normal phenotype. Also to compare how the 
phosphorylation pattern of downstream targets in the PI3K cascade such as AKT 
and FOXO differs between wildtype mice and the Pten conditional knock out 
mouse strain. 
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5. To investigate the action of the JAK-STAT signalling pathway component pSTAT5 
in ovarian granulosa cells and decipher the effects that pituitary hormones and 
extracellular ligands have on STAT5 phosphorylation. 
6. To examine the effects of extracellular ligands and hormones on pERK, a signalling 
intermediate of the Ras/Raf/MEKlERK cascade. 
7. To study the effect of constitutively active Ras on ovarian histology using the K-
rasGJ2D-Amhr2-Cre mouse strain and as a result of this investigate some ovarian 
signalling genes associated with senescence so as to determine the extent to which 
Ras activation impinges on vital upstream receptor genes that relay the FSH and LH 
message allowing successful folliculogenesis and ovulation. 
This study was carried out on mice of the required genotype that had been treated with 
gonadotrophin representing the normal physiological state to induce ovarian 
folliculogenesis, ovulation and luteinisation as required. Pregnant mare serum 
gonadotrophin (PMSG) an FSH analogue was used in place of FSH and human chorionic 
gonadotrophin (heG) an LH analogue was used in place of LH. 
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3.0 MATERIALS AND METHODS 
MATERIALS 
3.1 Materials Used for Animal Treatm.ent and Collection of Ovarian Material 
• VMR International Gonadotrophin Pregnant Mare Serum (PMSG) 4IU Cat No. 
80056-608 
• Human Chorionic Gonadotrophin (hCG) 51U (Gestyl; Diosynth, Oss, The 
Netherlands) 
• Saline 
• Estradiol 
• Propylene glycol 
• Decapitation guillotine 
• Forceps 
• Small sharp scissors 
• Magnifying glass 
• RIPA buffer (20mM Tris [PH 7.5], 15QmM NaCI, 1% Nonidet P-40, 0.5% Sodium 
Deoxycholate, 1mM EDTA, 0.1% SDS) 
• Roche complete mini protease inhibitor 
• Sonicator 
• Gibco Dulbecco's Modified Eagle Medium, Nutrient Mixture F-12 Ham IX 
(DMEMlFI2 1:1) Lot number 352081 
• Gibco Invitrogen Corporation Penicillin-Streptomycin Cat No: 15140-122 Lot No: 
1409377 
• Small petri -dishes 
• 26.5 gauge. needles 
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• Trypsin 
• Trypsin inhibitor 
• DNase 
• 12-well culture dish 
• Fresh bovine serum 
• Microscope 
• Testosterone National Hormone and Pituitary Program, Baltimore, Maryland 21201 
• Follicle Stimulating Hormone (FSH) National Hormone and Pituitary Program, 
Baltimore, Maryland 21201 (lOOng/ml) 
• Interleukin 6 (IL6) Research and Development (lOOng/ml) 
• Amphiregulin (Areg) Research and Development (100ng/ml) 
• Forskolin (Fo) Calbiochem (100ng/ml) 
3.2 Western Blot Materials and Solutions 
Materials 
• Protein samples. 
• BioRad Precision Plus Protein ™ Dual Color Standards Marker Cat No. 161-0374 
• BioRad glass plates, rack and electrophoresis tank Biorad, 2000 Alfred Nobel 
Drive, Hercules, CA 94547, USA. 
• BioRad 1.5 mm lOwell green comb 
• Fisher Scientific Methanol Code No. A412-4, Lot No.053816 
• Fisher Chemalert® Fisher Scientific® Acrylamide Code No. BP-170-500 
• BioRad Ammonium Persulphate (APS)- Cat No. 161-0700 
• BioRad TEMED-N,N,N' -N' -tetra-methylethylenediamine Cat No. 161-0801 
• Sigma 2-Mercaptoethanol M6250 Batch No. 12328HH 
• Fisher scientific Isobutanol Code No. A399-4, Lot No. 031612 
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• Bio-Rad Trans-Blot® SD. Semi-Dry transfer cell Serial NO.153BR 0146032 
• Bio-Rad extra thick blot paper mini blot size 7x 8.4cm, Cat No.1703966 
• Bio-Rad nitrocellulose or PVDF membrane 
• Cell signalling technologyTM Cyclin D2 Antibody Code No. 2924 (1: 1000) 
• Santa Cruz Biotechnology p27K1P Antibody Cat No. SC-528 (1: 1000) 
• Research and Development Systems phosphos-p27 (1: 1000) 
• Cytoskeleton Anti-Actin (Beta-Actin) Cat No. AANO 1 Lot No. 095 (1 :2000) 
• Cell signalling technologyTM MST -1 Antibody Code No. 3682 (l: 1000) 
• Cell signalling technologyTM Phospho-SAPKlJNK Antibody Code No. 92515 
(1 :500) 
• Cell signalling technologyTM PI3 kinase p 110 gamma antibody Code No.4252 
(1:300) 
• Cell signalling technologyTM Phospho-PDK 1 Code No. 30615 (1: 100) 
• Cell signalling technologyTM Akt antibody Code No. 9272 (1 :2000) 
• Cell signalling technologyTM phospho-Akt rabbit monoclonal antibody (P-AKT) 
Code No.4058L (1 :500) 
• Cell signalling technologyTM FOXO 1 Antibody Code No. 9462 (l :2000) 
• Cell signalling technologyTM Phospho-FKHR I Phospho-FOXOI Antibody Code 
No. 94615 (1:1000) 
• Cell signalling technologyTM Phospho-p70S6 kinase Antibody Code No. 92055 
(1:1000) 
• Santa Cruz Biotechnology C/EBP beta (C 19) Antibody Cat No. SC-150 (1 :300) 
• Cell signalling technologyTM phospho-STA T5 Antibody Code No. 9359 (1 :500) 
• Cell signalling technologyTM Phospho-p44/42 MAP kinase (Thr202/Tyr 204) 
Antibody I Phospho-ERK antibody Code No. 91015 (1 :1000) 
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• Biolabs New England p44/42 MAP kinase Antibody ITotal ERK Code No. 9102 
(1:1000) 
• ECL ™ Anti-Rabbit IgG HorseradishPeroxidase linked whole Antibody from 
donkey Cat NO.NA934V Lot No.362613 
• Western Super Signal® West Pico chemi-iluminescent substrate/ enhanced chemi-
iluminescent substrate for detection ofHRP (Solution A-Western Super Signal® 
West Pico Stable peroxide solution, Solution B-Western Super Signal® West Pico 
luminal/enhancer solution) 
• GE Healthcare, UK Limited Enhanced Chemical Luminescence (ECL) Lumigen™ 
PS-3 detection reagent Solution A (RPN2132Vllot 74) and 2Suls ofLumigen™ 
PS-3 detection reagent Solution B (RPN2132V2, lot 74) 
• Optical density quantifier: Molecular Dynamics Machine with Scanner control 
software: Image Quant S.2 
Solutions 
• I X SDS Electrophoresis Tank Buffer: Tris Base 3.02g, Glycine 14.40g, SDS 1.00g, 
dissolve this in appro x O.4mls of dH20 and then make this up to 1 litre (pH 7.S). 
• Semi-Dry Transfer Buffer: S.82g Tris Base, 2.93g Glycine, 20%methanol, 3.7Sg 
10% SDS, dissolve this in approx O.4mls of dH20 and then make this up to 1 litre. 
• Milk Blocking Buffer: 109 milk powder, 200mls TBST. 
• Stripping Buffer: lSmls dH20, Smls 4 X Tris/SDS ph 6.8, 0.14mls 
Betamercaptoethanol. 
• Tris Buffer Saline with Tween (TBST): 100ml of lOX TBS- (200ml 1M Tris pH 
7.S, 300ml SM NaCI, SOOml H20) + 900ml H20 + 2mls SO% Tween 20. 
SO 
Western Blot Gels 
8% lower resolving gel 
Mis 
30% ACt'ylamide 1.040 
4 X Tris/SDS ph 6.8 1.000 
dH20 1.960 
lO%APS 0.040 
TEMED 0.004 
5% upper stacking gel 
MIs 
30% Acrylamide 4.24 
4 X Tris/SDS ph 8.8 4.00 
dH20 7.76 
10% APS 0.16 
TEMED 0.01 
3.3 H&E Materials 
• PFA fixed processed paraffm embedded 7-um ovary sections 
• MENZEL-GLA ER® Super frost® Plus Microscope Slides. Art no. 
J1800AMNZ. 
• Histolab Xylene. Art Nt'. 02080 Fisher Scienti fic® Xylene- Code No. X5-4 
UN J 307 Lot No. 040649 
• Histolab® 99.5% ethanol 
• Histolab® 95% ethanol 
• Histolab® 80% ethanol 
• Histolab® Mayers Haematoxylin. AltNr. 01820 
• Eosin DPX mounting media 
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3.4 Immunofluorescence Staining 
Materials 
• Frozen sections embedded in OCT compound (Sakura Finetek USA, INC) fixed in 
4% PFA and sectioned at 7 Ilm 
• DAKOpen 
• Primary Antibodies: Santa Cruz Biotechnology p27kip (l: 1 00) Cell Signalling 
MSTI (l: 1 00), pSAPKlJNK (1: 100) pFOXO 1 (1: 100) 
• Invitrogen Molecular Probes, Eugene, Oregon, USA: Alexa Fluor® 594 Goat anti-
rabbit IgG (H+L) (red) AII080 Lot No:93El-1 
• Invitrogen Molecular Probes, Eugene, Oregon, USA: Alexa Fluor® 488 Goat anti-
rabbit IgG (H+L) (green) Al 1008 Lot No:45601A 
• Dapi counter stain (lOllg/ml) 
• MENZEL-GLASER® Super frost® Plus Microscope Slides. Art no. Jl800AMNZ 
• Light-proof humidity chamber 
• 80% Glycerol 
• Nail polish 
Solutions 
• 10 X Phosphate Buffered Saline (PBS): 80g NaCl, 2g KCL, 14.4g Na2HP04, make 
up to 1 litre with milli-Q water. 
• Paraformaldehyde (PFA) 4%: To make up 30mls, 1.2g of para formaldehyde 
EMDTM UN2213, Code No.PX0055, Lot No. 45105621 dissolved in 30mls of} X 
PBS solution or in 90°C water bath for 1 hour. Solution kept at 4°C and used within 
two weeks. 
• PBS/O.3% Triton X-IOO (PBS/Triton)1.5ml of20% Triton X-IOO added to lOOmIs 
of lXPBS 
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• Amersham Life Science BSA ... Bovine serum ,albumin albumin fraction V RIA 
grade Cat No. 70244 
3.5 Genotyping Materials 
• Extracted DNA 
• DNA digestion buffer with proteinase K 
• Phenol: chloroform: Isoamyl alcohol (25:24:1) 
• 100% ,70% Ethanol 
• Taq polymera,se, dNTPs, 
• TE Buffer(10mM Tris & ImM EDTA) 
• Amhr-2-Cre primers (Invitrogen) 
• Cyp-19-Cre primers (Invitrogen) 
• dH20, MgCh, lOX buffer 
• Heating block and eppendorftubes 
• 1.5% agarose gel 
• PCR machine 
• ISC Bio Express Gene Pure LE Quick Dissolve Agarose 500g Lot C405030 
3.6 RNA Extraction Materials 
• Qiagen RNeasy Mini® Kit Lot 42141618 
• Qiagen RNeasy Mini® Kit RL T buffer: Add 100~ds of beta-mercaptoethanol to 
lOmls ofRLT buffer (1:100). 
• 20.5 gauge syringes 
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METHODS 
3.7 Animal and Hormone Treatment Methods 
All mouse genotypes under study were housed under a 16 hour light: 8 hour dark schedule 
in the transgenic mouse facility in the centre of comparative medicine at Baylor College of 
Medicine, Houston, Texas. Immature female C57BLl6 mice were obtained from Harlan, 
Inc. (Indianapolis, IN), weighing between 20-30gms. The rat strain used was Holtzman, 
Sprague-Dawley, 26-28 days old females which weighed between 50-90gms. The rats 
were housed in the Taub Vivarium facility in Baylor College of Medicine. All animals 
were provided with food and water which they could take freely. Animals were treated 
under the National Institutes of Health Guide for the Care and Use of Laboratory Animals 
as approved by the Animal Care and Use Committee at Baylor College of Medicine. The 
knock-out/knock-in mice used are explained in Section 1.14. 
3.7(i) Method for mouse treatment 
Immature (day 21 of age) mice were sacrificed prior to and at 48 hours following injection 
ofPMSG. O.lml ofPMSG (41U dissolved in phosphate buffered saline) was administrated 
through the intraperitoneal route in order to stimulate development of preovulatory 
follicles. The mice killed prior to PMSG injection served as the not-treated samples (NT). 
PMSG-treated mice were killed at 2,4,8,12 and 16 hours following hCG (human chorionic 
gonadotrophin) administration. 0.1 ml of LH analogue, hCG (51U dissolved in saline) was 
injected into mice via the intraperitoneal route. hCG functioned to stimulate ovulation and 
luteinisation. For each time point ovaries were isolated and pooled from 5 mice. Mice 
were euthanised by manual restraint followed by cervical dislocation to prevent rapid stress 
related release of pituitary hormones (FSH, LH and ACTH) and brain peptides that occurs 
during the relatively slow process of chemically induced anaesthesia. The bolus release of 
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hormones in response to anaesthesia can impact and acutely alter the function of the tissues 
being studied, namely the ovaries. As well as this, the chemicals used for anaesthesia can 
themselves exert effects so this is why more rapid physical methods that did not involve 
chemicals were used. If the ovary was to be paraffin wax embedded, it was immediately 
frozen at -80°C once removed from the mouse. If the ovary was to be used for western blot 
analysis it was placed in an eppendorf containing 4mls of blue RIP A protein lysis buffer 
and 40fll of Roche mini protease inhibitor (1:100 dilution). It was important to keep 
everything on ice at this stage. A homogenous solution was made by sonicating the ovary 
emmersed in the RIP A lysis buffer, protease inhibitor cocktail. The ovary lysate was then 
centrifuged in a 4°C centrifuge for 5 minutes at top speed. 200fll of the supernatant was 
removed and put in a fresh eppendorf. Protein concentration was determined using 
Bradford Assay. 5 ovaries were pooled for each time point in the western blots. 30flg 
protein was added to each well of an 8% acrylamide gel: volume of 20fll diluted in RlPA 
protein lysis buffer 1.5flg/fll. This 8% acrylamide gel was run at 150volts until molecular 
weight marker had separated sufficiently so that protein of interest could be seen (approx 
45 minutes). 
3.7(ii) Method for rat treatment 
Immature rats were injected with O.2ml estradiol (l.5mg of estradiol was dissolved in O.2ml 
propylene glycol) subcutaneously for three consecutive days and sacrificed on day 3. Rats 
were euthanised by manual restraint followed by decapitation to prevent rapid stress related 
release of pituitary hormones (FSH, LH and ACTH) and brain peptides that occurs during 
the slower process of chemical induced anaesthesia. The chemicals themselves and also 
the release of such pituitary hormones may alter the natural state of the ovary being studied. 
At the time of sacrifice the ovaries were removed and granulosa cells isolated to use for cell 
culture. Four rats (8 ovaries) generated 12 mls of granulosa cell suspension. 
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3.7(iii) Method for collecting ovarian granulosa cells 
Rats were selected and sacrificed by decapitation. Cells were collected from rat ovary by 
puncturing the follicles with a 26.5 gauge needle while it was suspended in Gibco culture 
medium with penicillin streptomycin antibiotic added (1: 1 00). Cells were centrifuged for 
3.5 minutes at 2800rpms to get rid of apoptotic cells and cell fragments which were present 
in supernatant. Supernatant was poured off and cells were re-suspended in fresh medium. 
Iml of trypsin was added to the cells and monitored for approx 1 minute until precipitation 
occurred and cell fragments were evident in the supernatant. Immediately Iml of trypsin 
inhibitor was added along with 1.5ml of DNase. Cells were washed twice with fresh 
culture medium at 2800rpms for 3.5 minutes and re-suspended in an appropriate amount of 
culture medium depending on how many cell culture plates were being used. Cells were 
cultured at a density of 1 X 106 cells in 1 ml of culture medium in 12-well culture dishes 
that were serum coated to allow the attachment of the granulosa cells. 
3.7(iv) Method for culturing rodent granulosa cells 
Granulosa cells were cultured and used for western blotting analysis. This was carried out 
using 12 well culture dish coated with a 1 % fresh bovine serum solution for rats or a 5% 
fresh bovine serum solution for mice. This solution was made up using Gibco culture 
medium with penicillin streptomycin antibiotic added (l: 1 00) warmed to 37°C in the water 
bath. Approx 1 ml of serum solution was added to each well in the 12-well culture dish. 
The dish was then incubated at 37°C for at least 30 minutes. The serum contained 
fibronectin which coated the plastic culture dish and allowed the granulosa cells to attach 
easily. When the granulosa cells were isolated and ready to be used, the serum solution 
was pipetted off and wells were washed three times with serum free Gibco culture medium 
with penicillin streptomycin antibiotic added (1: 100). Cell were cultured in this medium 
overnight to allow their attachment to the dish bottom and the next day were treated with a 
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variety of different honnones such as Follicle Stimulating Honnone, Interleukin-6, 
Amphiregulin and Forskolin (lOOng/ml). After these various treatments, 100JlI of boiling 
RIP A lysis buffer was added to each well. This was pipetted up and down so as to ensure 
maximum protein extraction from all the granulosa cells. Samples from each well were 
then placed in labelled eppendorf tubes and boiled for a further 5 minutes. These samples 
were kept in the -80°C freezer until they were ready to be used for western blot analysis or 
if more appropriate 20JlI of sample were loaded to each well of an 8% acrylamide gel and 
ran at 150 volts for 45 minutes or until protein of interest has separated out. 
3.8 Performing Western Blot 
Ensuring glass plates are aligned straight, the gel apparatus for two 1.5mm thick gels was 
assembled. Resolving gel for two 1.5mm thick acrylamide gels were made up as outlined 
in the materials section, adding TEMED last. Before adding the 10JlI of TEMED, two 
200JlI aliquots of the gel mixture was taken out and placed in two separate eppendorf tubes. 
2.5JlI of TEMED was added to each tube. This 202.5JlI was pipetted into each gel 
apparatus and allowed sit for 5 minutes to seal the bottom of the gel. IOJlI ofTEMED was 
added to the rest of the mixture which was then distributed between each gel apparatus. 
200JlI of iso-butanol was added to the top of each gel mixture to remove air bubbles and 
ensure a straight line top on each gel. Gel was left to set for approx IS minutes. After this 
time gels were checked macroscopically to ensure interface had fonned and iso-butanol 
was poured off. 2 mls of stacking gel was then added on top of the resolving gel. 
Immediately well comb was put in place and gels were allowed to sit for a further 15 
minutes. The tank was filled with 1 X SDS Electrophoresis Buffer and gels placed inside. 
Comb was removed and SDS extracts containing 30Jlg protein were resolved by SDS-
PAGE (8%) and transferred to nitrocellulose/PVDF membrane. Gels were ran at 150 volts 
for approx 45 minutes and then removed and placed in semi-dry transfer buffer. The 
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hydrophobic PVDF membranes were washed in a few drops of methanol in order to make 
them permeable. Membranes were then washed in semi dry transfer buffer and immersed 
in fresh semi-dry transfer buffer with two lots of blotting towels. A few drops of transfer 
buffer were placed on the surface of the transfer chamber surface. One lot of blotting 
towels followed by the membrane and then the gel and a further lot of blotting towels were 
subsequently placed on the transfer chamber surface. During this procedure excess air was 
removed between each layer using a rolling pin. More semi-dry transfer buffer was placed 
on top of this sandwich and excess buffer from around the sides sucked up using a Pasteur 
pipette. The gel was transferred to the membrane on the transfer chamber at 15 V for 
45mins. Once fully transferred the membrane was blocked in 5% milk blocking solution 
for 30 minutes. During this time the primary antibody was made up. The membrane was 
incubated in the appropriate primary antibody diluted in blocking solution as outlined in the 
materials section to a final volume of 10mls. The membrane was agitated in a plastic 
pouch overnight at 4°C and subsequently washed three times in TBST for 10 minutes each. 
The membrane was then incubated in HRP-conjugated secondary antibody diluted (l :5000) 
in 10ml of 5% milk with gentle agitation for 30 minutes at room temperature. The 
membrane was washed in TBST three times for 10 minutes each and then patted dry on a 
paper towel. The ECL substrate (lml Solution A and 251l1s of Solution B) was applied to 
membrane for two minutes. Membrane was blotted on tissue paper and wrapped in a 
plastic sleeve. This was taped inside a labelled metal cassette that had been exposed to 
light for 10 minutes. In the dark room Kodak film was placed on top of the membrane and 
an initial 10 second exposure indicated the proper exposure time. Subsequently the 
membrane was exposed with new film for the appropriate time and developed. Membrane 
was rinsed briefly in TBST if it was to be probed with a different primary antibody. If the 
second protein overlapped with the first one then the membrane was stripped. Stripping 
Buffer was placed in a 50ml tube and allowed to heat up in 55°C incubator. Once buffer 
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had heated up the membrane was placed inside the tube. The membrane was left rotating 
inside the incubator for 30 minutes. After this time it was washed in TBST for 10 minutes, 
rinsed in milk and the new primary antibody was applied. Each western band was then 
measured on an optical density quantifier (Molecular Dynamics Machine) and analysed 
using scanner control software (Image Quant 5.2). 
3.9 Haematoxylin and Eosin Staining 
The required mouse ovary paraffin tissue sections were deparaffinised in three changes of 
xylene for ten minutes each. The sections were hydrated through a graded alcohol series, 
which included two changes in 100% ethanol for two minutes each and further rehydration 
through 95%, 70%, 50% ethanol and water for two minutes each. The sections were 
stained in new and unfiltered haematoxylin for 20-30 seconds and then transferred to 
running water to blue up. The eosin was applied to the sections for 20 seconds and rinsed. 
The sections were dehydrated through 95% ethanol for two minutes and through two 
changes of 100% ethanol for a minute each. The dehydrated sections were cleared in two 
changes of xylene for a minute and mounted in DPX mounting media. 
3.10 Immunofluorescence Method 
Frozen ovarian sections were selected and the outside of the tissue section was circled 
using a DAKO pen. Slides were fixed in 4% PFA in PBS for 30 minutes at room 
temperature. The PF A was aspirated off using a pipette and the sections were rinsed three 
times in PBS in a coplin jar for three minutes each. Sections were blocked and made 
permeable with 5% Bovine Serum Albumin (BSA) in PBS/Triton for 30 minutes at room 
temperature. The BSA was aspirated off and the primary antibody applied. The primary 
antibody was diluted 1: 100 in PB S/Triton and approx 150 f.lls was applied per tissue 
section. The slides were placed in a light proof humidity chamber and left at 4°C overnight. 
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The primary antibody was aspirated off and slides were washed three times with 1 X PBS 
in a coplin jar. Slides were incubated for 1 hour in the dark at room temperature with 
fluorochrome conjugated secondary antibody diluted in PBS/Triton. Secondary antibody 
Invitrogen Molecular Probes Alexa Fluor® 594 Goat anti-rabbit IgG (H+L) was typically 
diluted 1 :200 (red colour)/ Invitrogen Molecular Probes Alexa Fluor® 488 Goat anti-rabbit 
IgG (H+L) (1 :200) (green colour). Slides were counter stained with DAPI (10Ilgs/ml) 
diluted 1 :200 in PBS for 5 minutes (blue colour). Slides were rinsed once with 1 X PBS 
for 5 minutes in a coplin jar. Slides were mounted in lOll1 of 80% glycerol and the edges 
of the covers lips were sealed with nail varnish to stop the sections drying out. The slides 
were left in a light-proof box at 4°C and examined within a week using appropriate 
excitation wavelength. 
3.11 Genotyping AMHR2-CRE and CYP19-CRE mice 
Mouse-tail snips were digested in 600 III of DNA digestion buffer/ proteinase K solution at 
55°C overnight. Tubes were centrifuged at full speed for 5 minutes so as to force the 
mouse fur to the bottom of the tube. 400111 of supernatant was pipetted off and added to 
Iml of 100% Ethanol. This was mixed well and centrifuged at 1400rpm for 10 minutes. 
The supernatant was discarded and the pellet washed with 200llls of 70% Ethanol. The 
ethanol supernatant was then discarded and the pellet was left to dry in the 55°C incubator 
for 10 minutes. 500lli ofTE Buffer (10mM Tris & ImM EDTA) was added to the pellet to 
help the DNA dissolve. Tubes were vortexed vigorously and placed in the 55°C incubator 
for 10 minutes again. This genomic DNA was used to genotype the mice by PCR using 
standardised reagents and optimised PCR programmes. 1 III of genomic DNA was added to 
each tube along with 19J1ls of premix to give a final volume of201lis per tube as outlined in 
the table below: 
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Reagent Volume per tube 
bd) 
Genomic DNA (l~g/~1) 1 
Primer mix: Amhr2-Cre (lOOllgl~l) 3 
Cyp-19-Cre (801lgl~1) 
Invitrogen 5 X First Standard Buffer Lot 1172260 4 
Prom ega MgCh (25mM) 2 
dNTPs (2mM) 1 
DNase free H2O 8.8 
Prom ega Go Taq<!Y Flexi DNA Polymerase 5U/~1 0.2 
NOTE: Amhl'2-Cl'e primers: CGCA TTGTCTGAGTAGGTGT (forward) 
GAAACGCAGCTCGGCCAGC (reverse) 
CypJ9-Cre primers: TCTGATGAAGTCAGGAAGAACC (forward) 
GAGATGTCCTTCACTCTGATTC (reverse) 
The two PCR programmes used were as follows: 
Cyp-19-Cre Programme Amhr2-Cre Programme 
1. 94°C- 2 minutes 1. 94°C-3 minutes 
2. 94°C-30 seconds 2. 94°C-30 seconds 
3. 94°C-30 seconds 3. 60°C-30seconds 
4. 72°C-30 seconds 4. 72°C-l minute 
5. Go to step 2-30X (cycles) 5. Go to step 2 -35X (cycles) 
6. 72°C- 5 minutes 6. 72°C-5minutes 
7. 15°C forever 7. 15°C forever 
Note: The genotype of Pten and R26R mice were previously confirmed. 
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After PCR was complete, 10J.lI of each sample was loaded on a 1.5% agarose gel with a 
positive and negative control. Gel was run at 200 volts for 20 minutes. Samples were 
allowed to run halfway down the gel and were then photographed under a UV light. 
Making 1. 5% agarose gel 
2.5g of agarose powder was dissolved in 150mls of 1 X TBE in a 500ml conical flask and 
microwaved for 2 minutes. The mixture was removed and swirled for 30 seconds before 
placing it back in the microwave for a further 2 minutes. When agarose mixture started to 
boil, flask was removed from microwave and allowed to cool at room temperature (22°C) 
on magnetic stirrer. 12J.lI of Ethidium Bromide was added to agarose mixture and gel was 
poured in 4°C cold room and allowed to set for approx 30 minutes. Samples for genotyping 
were loaded along with molecular weight marker. 
3.12 RNA Extraction 
m-RNA Extraction from cultured cells using Qiagen RNeasy Mini® Kit 
After incubation and cell treatment the culture medium was aspirated off and 350J.lls of 
RL T clear cell lysis buffer was added to each well. Samples were put into separate 
eppendorf tubes and placed in -80°C freezer. m-RNA was then extracted from these 
samples using RNeasy kit. Firstly samples were passed at least five times through a 20.6 
gauge needle (0.9mm diameter) fitted to an RNase-free syringe. 350J.lI of 70% ethanol was 
added to this homogenised lysate and mixed well with a pipette. This was then transferred 
to an RNeasy mini column placed in a 2ml collection tube. The tube was closed gently and 
centrifuged for 15 seconds at 8000 x g. The flow through was discarded and 700J.lI of 
buffer RWI was added to RNeasy column. The tube was closed gently and centrifuged for 
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15 seconds at 8000 x g in order to wash column. The flow through and collection tube 
were then discarded. The RNeasy column was transferred to a new 2ml collection tube. 
500fll of buffer RPE was pipetted onto column and the tube was closed gently and 
centrifuged for 15 seconds at 8000 x g to wash column. The flow through was discarded 
and another 500fll of buffer RPE was added to the column. The tube was closed gently and 
centrifuged for 2 minutes at 8000 x g to dry RNeasy gel membrane. 30fll of RNase free 
water was pipetted directly onto membrane and tube closed gently and centrifuged for 1 
minute at 8000 x g. The m-RNA was stored at -80DC until RT-PCR was performed. 
3.13 RT-PCR: Obtaining c-DNA from m-RNA using rodent granulosa cells 
Final volume of 40flls per tube 
Reagent Volume per tube 
btl) 
Mouse mRNA (Rat mRNA use 5 fll) 20 
Invitrogen 5 X First Standard Buffer 8 
Lot 1172260 
Invitrogen DTT Lot 1382315 (100mM) 4 
Oligo dT Lot 316256 (500ng/fll) 2 
dNTP (2mM) 2 
Invitrogen RT enzyme Lot 1393450 (200U/fll) 1 
DNase RNase free H20 (Rat use 18 fll) 3 
20fll of each mRNA sample (or 5fll in the case of rat granulosa cells) was placed into 
separate eppendorf tubes and a premix of the other components was made up depending on 
how many samples were being reverse transcribed. Each tube contained a final volume of 
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40f.l1. PCR was then carried out: 37°C for 45 minutes, 65°C for 15 minutes and 15°C 
forever. If the signal proved to be too weak, 32p isotope was used to amplify the response 
as outlined in Section 3.14 below. 
3.14 Method to determine linear range of genes of interest 
(kit ligand, p15,p16. p19) 
Linearisation tests were carried out using template c-DNA. A series of dilutions ofthe 
c-DNA template was made to determine the optimum number of cycles to use in 
radioactive PCR as outlined in table below. 
Sample No. Sample H20 <1d) Corresponding 
Cycle Number 
1 12 f.ll Template eDNA 0 34 
2 3 f.ll Template eDNA 9 32 
3 3 f.ll Sample 2 9 30 
4 3 f.ll Sample 3 9 28 
5 3 f.ll Sample 4 9 26 
2f.l1 ofc-DNA Samples No.1-5 were added tol8f.l1 of premix. llli of 32p (MP dCTP -Alpha 
32P Lot J8Y dCX4 3000Ci/mmol) was added to 9f.l1 of H20 and then I III of this diluted 32p 
mixture was added to the premix. 18 f.ll of premix and 2111 of c-DNA were then added to 
each tube as below: 
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Reagent Volume per tube 
btl) 
cDNA 2 
Invitrogen CIEBP~ ICyclophilin Ikit ligand I p 15 I 2 
p161 p19 primers (lOOllg/lll) 
dNTPs (2mM) 2 
Promega 5 X Green Go Taq<l!! Flexi Buffer 4 
Prom ega MgCh (25mM) 2 
Promega Go TaqC!lJ Flexi DNA Polymerase (5U/Ill) 0.2 
DNase RNase free H2O 7.8 
PCR was carried out as follows: 
Step Temperature (OC) Time (Minutes) 
1 94 3 
2 94 0.3 
3 60 0.3 
4 72 0.3 
5 Step 2,3,4 Repeated 33 times 
6 72 5 
7 15 Forever 
Each sample was then ready to be loaded onto a polyacrylamide gel. 
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Making 17.5cmX 16cm Polyacyrlamide gel 
Solution MIs 
30% acrylamide 6.64 
dH20 29 
5XTBE 4 
10%APS 0.4 
TEMED 0.04 
The gel was poured between two clean glass plates and allowed set for 30 minutes. Comb 
was then removed and gel was placed in tank buffer. lOJlI of sample was loaded into each 
well. Loading dye was loaded into the last well in order to know which direction samples 
were going in. The gel was run at 150 volts for 30 minutes. It was then removed from the 
glass plates and placed on top of two sheets of filter paper. The gel and two sheets of filter 
paper were placed on the gel dryer (filter paper on the bottom) and covered with cling film. 
The valve on the gel dryer was closed and temperature set to 80°C. The gel was allowed 
dry for 55 minutes. At this point the gel attached to one sheet of filter paper. The other 
sheet of filter paper was disposed of in the radioactive waste. The sheet of filter paper with 
the gel attached was then placed inside a cassette and exposed to an x-ray film in the 
darkroom. An initial 10 second exposure helped to determine how long the x-ray film 
should have been left on for. If no bands were seen the cassette with x-ray film was placed 
in -80°C freezer for 2 hours. Each band was then examined macroscopically and the 
optimum number of cycles for a particular set of primers was determined. A PCR using the 
optimum cycle number and the appropriate primers was then carried out as outlined above 
(start of Section 3.14). 
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4.0 RESULTS 
The pituitary gonadotrophins follicle stimulating hormone (FSH) and luteinising hormone 
(LH) are the primary stimuli for the growth and differentiation of preovulatory follicles. 
FSH stimulates granulosa cell proliferation, follicle growth, and the production of estrogen. 
Once follicles reach the preovulatory stage the LH surge initiates the meiotic resumption of 
oocytes, the expansion of cumulus cells, and ovulation. After ovulation the remained 
follicle cells differentiate into luteal cells and produce progesterone to prepare for 
pregnancy. The pituitary gonadotrophins have the capability of activating various 
molecular pathways such the PI3K1AKT/FOXO pathway and the Ras/Raf/MEKlERK 
pathway. Such pathways are involved with cell proliferation, cell survival and cell cycle 
arrest. G] is the start of the cell cycle and this is entered when the cell senses growth 
signals or mitogens such as FSH or LH. 
Fig 4.1: The pituitary gonadotrophin function in the ovarian cycle 
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Fig 4.1: Follicle Stimulating Honnone (FSH) functions in the maturation of the ovum over time from primary 
follicle to antral follicle, followed by a Luteinising Honnone (LH) surge which results in ovulation and the 
development of the corpus luteum in the empty follicle. 
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Cellular proliferation and differentiation are fundamental biological processes controlled by 
extracellular signals that impinge upon cell cycle regulatory machinery and modulate gene 
expressIOn. Two key classes of regulatory molecules, Cyclins and Cyclin-Dependent 
Kinases (CDKs), determine a cells' progress through the cell cycle. CDKs are 
constitutively expressed in cells whereas cyclins are synthesised at specific stages of the 
cell cycle, in response to various molecular signals from different molecular pathways. In 
the ovary, hormones control the development of individual follicles by triggering 
sequential, dynamic changes in granulosa cell proliferation and gene expression (Hadley et 
al 2007). In the case of the PI3K1AKT/FOXO and the Ras/Raf/MEKIERK pathway, 
FSH/LH bind to its G-protein coupled receptor which in tum activates Cyclin D2 to start 
the cell cycle. Cyclin D2 has been shown to be specifically localised to the granulosa cells 
of growing follicles (Robker and Richards 1998b). The Cyclin D2/CDK4 complex can 
then activate E2F responsive genes by phosphorylation. Different Cyclin-CDK 
combinations determine which downstream proteins will be targeted. A protein called 
p27Kipl can inhibit Cyelin D2 and thus cause cell cycle arrest. Protein kinase B (AKT) can 
repress p27Kipl • In the ovaries, Cyclin D2 expression has been shown to be crucial for the 
proper growth of granulosa cells with the follicle. Female mice carrying a null mutation on 
the Cyclin D2 gene are infertile because of impairment in granulosa cell proliferation in 
response to FSH, resulting in small follicles with trapped oocytes (Robker and Richards 
1998b). In non-growing, primordial follicles, a single layer of granulosa cells arrested in 
Go surrounds the oocyte. In response to unknown signals, primordial follicles leave the 
resting pool and granulosa cells initiate a phase of growth in which proliferation is 
exceedingly slow. 
To investigate the importance of the PI3K1AKT/FOXO and 
Ras/RafIMEKiERK cascades in this process of proliferation and differentiation, 
downstream targets from each pathway were selected and studied. This was accomplished 
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by injecting 3 week old mice with PMSG and 48 hours later with heG at various time 
points to mimic the effects ofFSH and LH as explained in Section 3.7(i). Protein was then 
extracted from whole ovary lysates and western blot analysis carried out. Firstly the 
expression pattern of critical cell cycle regulators eyclin D2 and p27Kip1 was examined. 
Fig 4.2a: Western blot analysis of cell cycle regulators 
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Fig 4.2a: Shows a western blot of wild type mouse whole ovary lysate for Cyclin D2, p27Kip1 and 
phosphorylated p27Kip1 (pp27kiP1 ) expression. Expression is shown for immature non-treated (NT), pregnant 
mare serum gonadotrophin (PMSG) treated and hCG (human chorionic gonadotrophin) treated wild type mice 
at different time points (2,4,8,12 and 16 hours) post treatment. Beta Actin is used as a loading control. 
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Fig 4.2b: Optical Density Quantification of Western Blots shown above 
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Fig 4.2b: Each western blot band was measured on an optical density quantifier (Molecular Dynamic 
Machine) and analysed using Scanner Control Software Image Quant 5.2. A volume and an area 
measurement were obtained for each band. An intensity index was then calculated using these results and a 
normalised value which was obtained for each band was plotted on this graph. 
Levels of Cyclin D2 remain relatively stable throughout the hCG series. It is known that 
Cyelin D2 is a critical factor needed for cell cycle initiation and progression. p27KipJ is 
down regulated first at 2,4,8, 12 hours post hCG but is then up regulated at 16 hours when 
cells have started to luteinise (Fig 4.1). It is at this time point that ovulation occurs and the 
oocyte is released. The ovulated follicle now develops into a corpus luteum. The cell cycle 
stops after hCG treatment so essentially granulosa cells stop proliferating and start to 
differentiate. Phospho-p27KipJ (pp27KipJ ) protein levels decrease slightly at 16 hours post 
hCG which is mirrored by an increase in total p27Kipl . From the hCG 2 hour time point 
onwards there is an inverse relationship between total p27KipJ levels and phospho_p27Kip1 
levels (Fig 4.lb). To determine the localisation of p27kip1 within the ovary some 
immunofluorescence staining was carried out on PMSG treated and 16 hours post hCG 
treated frozen ovary sections. Results showed that p27Kip1 was present in some of the 
developing primary follicles, mainly the larger more developed ones (Fig 4.3) and also in 
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the oocyte after PMSG treatment for 48 hours. 16 hours post heG treatment, luteal cells 
stained positively for p27Kip1 (Fig 4.2). 
Fig 4.3: p27Kipl immunofluorescence staining of wild type mice frozen ovary sections 
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Fig 4.3: Showing p27kipl staining (green colour) and DAPI (blue colour) counter staining in PMSG treated 
(A, C) and 16 hours post hCG (B, D) treated ovary sections. p27kipl staining more intensely 16 hours post 
hCG after luteinisation has occurred and luteal cell differentiation commenced. A negative control which had 
not been treated with any primary antibody was included showing no green p27kiPI positive staining. 
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Apoptotic markers 
The PI3K1AKT/FOXO and Ras/Raf/MEKIERK pathways provide signals for many types 
of somatic cells. One function of these pathways in the ovary may be the survival of 
granulosa cells. To understand this better, two factors connected with apoptosis were 
investigated: Mammalian Ste20-like kinase (MSTl) and stress-activated protein 
kinase/Jun-amino-terminal kinase (Phospho-SAPKlJNK). Oxidative stress activates the 
MSTI JNK pathways that phosphorylate FOXOI at a conserved site within the forkhead 
domain that promotes FOXO nuclear translocation and thereby induces cell death (Lehtinen 
et al 2006) (Fig 1.10(i)). To examine the effects of FSH/LH treatment on MSTI and p-
SAPKlJNK, 3 week old mice were injected with PMSG first and then 48 hours later with 
hCG at different time points. 
Fig 4.4: Western blot analysis of some apoptotic markers 
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Fig 4.4: Shows a western blot of wild type (WT) whole mouse ovary lysate using mammalian Ste20-like 
kinase (MSTl) and phosphorylated stress-activated protein kinase/lun-amino-terminal kinase (p-SAPK/JNK) 
antibodies. Protein expression is shown for immature non treated (NT), pregnant mare serum gonadotrophin 
(PMSG) treated and heG (human chorionic gonadotrophin) treated wild type mice at different time points 
(2,4,8,12 and 16 hours) post treatment. The red line symbolises where ovulation has occurred. Beta actin 
was used as a loading control. 
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The protein levels of both apoptotic markers remained unchanged at each time point in the 
western blot heG series. It would appear that ovarian cells rely on apoptotic signals other 
than MSTI and phospho-SAPKlJNK to control their apoptosis. To investigate the 
localisation of MSTI and pSAPKlJNK within the ovary, immunofluQrescent staining was 
carried on out some frozen ovary sections. MSTI and pSAPKlJNK gave a very similar 
staining pattern. Theca cells stained more intensely than other cells within the ovary. 
PMSG treated ovaries show a slightly more positive staining pattern than non-treated 
immature follicles. In the PMSG treated ovary section, the oocyte stained intensely with 
the. pSAPKlJNK antibody. 
73 
Fig 4.5: Immunofluorescence staining of apoptotic markers MSTI and pSAPKlJNK 
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Fig 4.5: Mammalian Ste20-like kinase (MSTl) red staining of frozen non-treated (NT) ovary under 5X 
magnification (A) and lOX magnification (B). MSTl staining non-treated (NT) ovary sections viewed under 
40X magnification (C), with (D) and (E) separately showing the red MSTl staining and blue DAPI staining 
respectively. (F) depicts phosphorylated stress-activated protein kinase/Jun-amino-terminal kinase 
(pSAPK/JNK) red staining of frozen non-treated (NT) sections viewed under 5X magnification and (0) lOX 
magnification. (H) PMSO treated section viewed under 40X magnification, clearly showing theca cell 
positivity with (I) and (J) separately showing red pSAPK/JNK staining and blue DAPI staining respectively. 
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Investigation of the phosphorylation pattern of downstream targets of 
PI3K1AKTIFOXO pathway 
Having looked at a number of cell cycle regulators and some markers of apoptosis it was 
now necessary to investigate the phosphorylation of specific PI3K components downstream 
of the FSH/LH receptor. The mechanism by which FSHlLH receptors activate PI3KI AKT 
pathway has as yet not been determined. In other systems however, Ras has been reported 
to inte.ract with PI3K directly and activates the whole pathway as explained in Section 
1.10(ii). PI3K is a lipid kinase that catalyses the transformation of PIP2 into PIP3• As a 
membrane-associated second messenger, PIP3 induces the activation of PDK1I2 and AKT 
sequentially. AKT is a multi-functional kinase which promotes cell proliferation and cell 
survival by phosphorylating many target molecules. One important target of AKT in 
granulosa cells is the transcription factor FOXO 1. FOXO factors repress cell proliferation 
and promote apoptosis. AKT activation induces the nuclear export and degradation of 
FOXOI by phosphorylation. When AKT is phosphorylated it can also phosphorylate 
p70S6kinase which is concerned with regulating protein translation and synthesis (Fig 4.6). 
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Fig 4.6: Overview of downstream phosphorylation pattern in the PI3K1AKTIFOXO 
pathway 
Regulate protein translation 
and Synthesis 
PI3K 
(pUOy) 
FOXOI 
Represses cell proliferation 
aDd promotes apoptosis 
Fig 4.6: p110gamma is the catalytic subunit of PI3K. PDK1I2 are the activating kinases which 
phosphorylated protein kinase B (AKT). pAKT then activates p70S6K or it can phosphorylate the 
transcription factor forkhead box 01 (FOXOl) rendering it inactive. 
A wildtype heG series was used to look more closely at some key intermediates in the 
PI3K1AKTIFOXO pathway and to monitor the changes in protein expression. Firstly to 
consider the step of the pathway where pllOy the catalytic subunit ofPI3K results in PDKl 
phosphorylation, pllOy levels and the phosphorylated form of PDKI (PPDKI) were 
investigated using western blot analysis. 
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Fig 4.7: Western blot analysis to investigate the phosphorylation pattern of 
downstream targets of the PI3K1AKTIFOXO pathway 
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Fig 4.7: Shows a western blot of wild type (WT) whole mouse ovary lysate for p 11 Oy (phosphorylated 110 
gamma subunit) and pPDKI (phosphoinositide dependant protein kinase 1) expression. Expression is shown 
for immature non-treated (NT), pregnant mare serum gonadotrophin (PMSG) treated and heG (human 
chorionic gonadotrophin) treated wild type mice at different time points (2, 4, 8, 12 and 16 hours) post 
treatment. Beta Actin is used as a loading control. 
p 11 ~ levels remain constant until the 16 hour post heG time point indicating once 
ovulation occurs there is a decrease in p 11 ~ protein level as a result of granulosa cells 
beginning to develop into luteal cells. Phosphorylated PDKI levels are at their highest at 2 
and 4 hours post heG as this is the point when cells start to proliferate and follicles start to 
develop from the pre-antral stage. Protein expression then reverts back to NT, PMSG 
levels at the 8, 12 and 16 hour post heG time points. This would indicate that the 
PI3K1PDKlIAKT pathway is at its most active when follicular cells are proliferating and 
growing before luteinisation occurs. Further downstream targets of PDKI were also 
investigated using a heG timecourse (Fig 4.8). 
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Fig 4.8a: Western blot analysis to investigate the phosphorylation pattern of 
downstream targets in the PI3K1AKTIFOXO pathway 
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Fig 4.8a: Shows a western blot of wild type (WT) whole mouse ovary lysate for total unphosphorylated 
Protein Kinase B (AKT), which is also used in this case as a loading control, phosphorylated protein kinase B 
(pAKT), total unphosphorylated forkhead box 01 (FOX01), phoshorylated forkhead box 01 (pFOX01) and 
phosphorylated p70S6 kinase (pP70S6k) expression, Expression is shown for immature non-treated (NT), 
pregnant mare serum gonadotrophin treated (pMSG) and hCG (human chorionic gonadotrophin) treated wild 
type mice at different time points (2, 4,8, 12 and 16 hours) post treatment. 
Fig 4.8b: Optical Density Quantification of Western Blots shown above 
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Fig 4.8b: Each western blot band was measured on an optical density quantifier (Molecular Dynamic 
Machine) and analysed using Scanner Control Software Image Quant 5.2. A volume and an area 
measurement were obtained for each band. An intensity index was calculated from these results and a 
normalised value obtained for each band and plotted on this graph. 
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In the immature untreated wild type ovaries, phosphorylated AKT expression was low to 
absent. pAKT, the activated form of the protein kinase B intermediate, was induced by 
PMSG, 2 and 4 hours post heG treatments in the wild type mouse. p-AKT expression was 
shown to be moderately induced by PMSG treatment. A greater induction was evident two 
hours post heG treatment and at 4 hours post heG treatment induction was down regulated. 
Expression was therefore highest 2 hours post heG treatment in the wild type ovary lysate. 
At 12 hours and 16 hours post heG treatment pAKT expression decreased to almost absent 
levels in the wild type mouse (Fig 4.8a, 4.8b). There is perhaps a transient phosphatase 
acting to downregulate pAKT. 
Total FOXO I levels are highest in the immature non-treated and 
PMSG treated ovaries. After heG treatment the levels ofFOXOl start to fall and at the 12 
and 16 hour post heG time points, the protein expression is nearly undetectable indicating 
that once differentiation and luteinisation occurs, total FOXO 1 is not longer needed in such 
abundance as when follicles are developing. The removal of total FOXOI correlates with 
the increase in the phosphorylated form of FOXOI (PFOXOl) at 12 and 16 hours post 
heG. In fact, once heG has been administered, even at the 2 hour time point there is an 
increase in pFOXO 1 protein expression. The smaller immature follicles of the non-treated 
and PMSG treated ovaries do not experience this rapid phosphorylation of FOXO 1. In 
these earlier developing and proliferating follicles, total FOXO protein levels rather than 
pFOXO 1 levels are high. The transient increase of pAKT suggests that AKT 
phosphorylation is important in getting the ball rolling as regards FOXO 1 phosphorylation 
but then perhaps another kinase takes over. pP70S6 kinase protein levels remain relatively 
constant after heG treatment, decreasing slightly at the 16 hour time point where 
luteinisation occurs. 
Frozen ovary sections were stained with pFOXO 1 antibody to assess if 
pFOXOl was changing localisation in the PMSG treated ovaries as opposed to ovaries that 
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had been treated with hCG for 16 hours. Both PMSG treated and hCG treated sections 
however showed a punctuated cytoplasmic type staining pattern (Fig 4.9). 
Fig 4.9: pFOX01 immunofluorescence staining of wild type frozen ovary sections 
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Fig 4.9: Showing pFOXOl staining (green colour) and DAPI (blue colour) counter staining in PMSG treated 
(A) and (B) and 16 hours post hCG treated (C) and (D) frozen ovary sections. 
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To investigate how extracellular ligands affect the PI3K1AKTIFOXO pathway 
To understand AKT phosphorylation better, some cell culture work using rat granulosa 
cells was carried out. Amphiregulin (Areg), Follicle Stimulating Hormone (FSH) and 
Interleukin 6 (IL6) are thought to be strong activators of the PI3K1AKT/FOXO pathway. 
Areg is an epidermal growth factor (EGF) which is induced in the rat ovary by 
gonadotrophin treatment. The role of rat amphiregulin in the ovary is unknown. Previous 
studies have shown that ovarian expression of rat amphiregulin coincides with that of 
cyclo-oxygenase-2 (COX2) and progesterone receptor (PR), both of which are known to 
play integral roles in ovulation. These observations suggest that rat amphiregulin is 
induced by the preovulatory LH surge, and may be associated with ovulatory events since 
amphiregulin and epiregulin act as mediators of LH action in the mammalian ovulatory 
follicles (Sekiguchi et al 2004). Regulation of the expression of these factors may open 
new possibilities in treatment of ovarian malfunction implicated with ovarian hyper-
stimulation. FSH is the principal regulator of follicular growth and maturation. As 
mentioned in Section 1.13 (i), Interleukin 6 (IL6) has previously been demonstrated to 
directly influence FSH differentiated functions of ovarian granulosa cells (Van der Hoek et 
al 1998). To investigate AKT phosphorylation from an extracellular point of view, 
granulosa cells were treated with these inducers (Areg, FSH and IL6) for 5, 10 and 30 
minutes. 
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Fig 4.10: Western blot results of rat granulosa cells cultured overnight and then 
treated with extracellular ligands 
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Fig 4.10: Rats were injected with estradiol for 3 consecutive days before granulosa cells were isolated and 
cultured overnight in culture media at 37°C. Ligands Amphiregulin (Areg), Follicle Stimulating Hormone 
(FSH) and Interleukin 6 (116) were added for 5, 10 or 30 minutes just before cells were harvested. The 
control lane on the left was not treated with any ligands. Beta-Actin was used as a loading control. 
All the ligands display the ability to induce AKT phosphorylation when compared to the 
control lane. Areg shows a uniform induction of AKT phosphorylation at 5, 10 and 30 
minute time points. FSH has the strongest ability out of the three ligands used to induce 
AKT phosphorylation, showing most phosphorylation between the 5 minute and 10 minute 
treatment time points. IL6 also displays the ability to induce AKT phosphorylation, 
showing the largest amount of pAKT expression at 5 and 10 minute time points and 
decreasing slightly after 30 minutes oftreatment (Fig 4.10). 
Rat granulosa cells were also cultured with culture media alone 
overnight and with culture media containing FSH and Testosterone (FSHlT) overnight. 
Treatment with FSH/T results in androgen being converted to estrogen by aromatase. This 
treatment means better induction of the LH receptor and better cytokine cleavage. 
Estradiol is important for facilitating induction of many genes which are present in the pre-
ovulatory follicle. Rat granulosa cells were again cultured overnight at 37°C and then 
treated with FSH, IL6, Areg, and Forskolin (Fo) for ten minutes. Forskolin is commonly 
used to raise levels of cyclic AMP (cAMP) in the study and research of cell physiology. 
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Forskolin resensitises cell receptors by activating the enzyme adenylyl cyclase and 
increasing the intracellular levels of cyclic Adenosine Monophosphate (cyclic AMP or 
cAMP). Cyclic AMP is an important signal carrier that is necessary for the proper 
biological response of cells to hormones and other extracellular signals. It is required for 
cell communication in the hypothalamus/pituitary gland axis and for the feed-back control 
of hormones. It acts by activating protein kinase A. 
Fig 4.11: Western blot results of rat granulosa cells cultured overnight in media only 
and in media containing FSH and Testosterone 
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Fig 4.11: Rats were injected with estradiol for 3 consecutive days before granulosa cells were isolated and 
cultured overnight in culture media only at 37°C and in culture media containing FSH and testosterone 
(FSHlT). FSH was added to media only samples for 5, ) 0 and 30 minutes just before cells were harvested. 
Forskolin (Fo), Amphiregulin (Areg) and Interleukin 6 (IL6) were added to granulosa cells in FSHIT media 
for 10 minutes just before cells were harvested. Both control lanes were not treated with any ligands. Beta-
Actin was used as a loading control. 
FSH induces AKT phosphorylation in the cells that have been cultured overnight in media 
only at 5, 10 and 30 minute time points. Fo, Areg and IL6 all show the capability to induce 
AKT phosphorylation compared to the control sample which was not treated with any 
ligand. Ifwe compare the 10 minute Areg time point in Fig 4.10, where culture media 
alone has been used, with the Areg 10 minute time point in Fig 4.11 where granulosa cells 
have been incubated with FSHIT overnight, Areg shows a stronger ability to induce AKT 
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phosphorylation when cells are incubated with FSHIT overnight. The same could be said 
for IL6 results in Fig 4.10 and Fig 4.11, i.e. granulosa cells incubated in FSHIT containing 
media results in an increase in pAKT levels. 
CIEBPP 
The transcription factor C/EBP~ is induced promptly in the ovary, as a response to an 
ovulatory dose of gonadotrophins. A specific reduction in ovarian C/EBP~ expression 
inhibits ovulation. In such ovaries, oocytes appear to be entrapped within the follicle. It 
has been shown that there is a correlation between the expression level of the activating 
isoform of C/EBP~ and the number of oocytes ovulated in response to gonadotrophins (Pall 
et al 1997). Since a reduction in CIEBP~ expression does not affect the level of the 
ovulatory mediator cyclo-oxygenase-2 (COX2), these findings support the view of CIEBP~ 
being an important factor in the ovulatory process and highlight a CIEBP~-dependent and 
COX-2-independent pathway that takes part in the regulation of ovulation (Sternick et al 
1997). CIEBP~ is induced very promptly in response to an ovulatory dose of LH. Within 
30 minutes after administration of an ovulatory dose of hCG, CIEBP~ mRNA can be 
detected in the ovary. C/EBP-~ acts as a regulator of COX2 expression (Sirios et al 1993). 
To investigate how CIEBP~ compares to other downstream targets in the 
PI3K1AKT/FOXO pathway and potentially elucidate the role it plays in ovarian cell 
proliferation and differentiation, western blot analysis was carried on a hCG series. 
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Figure 4.12: Western blot analysis to investigate CIEBPP expression in the ovary 
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Fig 4.12: A western blot of wild type mouse whole ovary lysate for CIEBP~ expression. Expression is shown 
for non- treated immature (NT), pregnant mare serum gonadotrophin (PMSG) treated and hCG (human 
chorionic gonadotrophin) treated wild type mice at different time points (2, 4, 8,12 and 16 hours) post 
treatment. Beta Actin is used as a loading control. 
C/EBP~ is present at 2, 4, 8, 12 and 16 hour time points. Previous studies show ERK is 
present in NT and PMSG treated samples (Fan et al 2008b). C/EBP~ comes later than this 
so we hypothesise that it is downstream of ERK. It was now necessary to look at a longer 
hCG time course to see if CIEBP beta is still present after 16 hours hCG treatment. m-
RNA was extracted from rat whole ovary lysates. Reverse Transcriptase PCR was carried 
out using this m-RNA in order to make c-DNA. A PCR was then carried out on this c-
DNA, using CIEBP beta primers and a radioactively labelled 32p dCTP isotope. The 
samples were run in a polyacrylamide gel, dried on a gel dryer and transferred to a sheet of 
filter paper. This was then placed in a cassette and developed in the dark room using x-ray 
films. 
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Fig 4.13: CIEBPP expression using a longer bCG time course. 
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Fig 4.13: mRNA was extracted from mouse granulosa cells and a RT-PCR carried out to make c-DNA. A 
PCR using radioactively labelled 32p dCTP was then carried out to investigate C/EBP~ expression using a 
longer time course of hCG treatments. Upper band is LAP 21-kDa and lower band is LIP 14-kDa. 
CIEBP~ is induced at 16 hrs and decreases progressively as the days go on. There are two 
forms of CIEBP~, LAP (liver-enriched transcriptional activator protein), and LIP (liver-
enriched transcriptional inhibitory protein). In Fig 4.13 the upper band is LAP 21-kDa and 
the lower band is LIP 14k-Da. LIP is the truncated form of LAP which acts as an internal 
negative regulator. LIP lacks an N-terminal domain so cannot bind to DNA. C/EBP~ 
functions mainly up to 2 days post hCG and is then quickly down-regulated after this time 
point onwards. 
As discussed earlier, FSH and Areg are extracellular ligands with the ability to 
induce AKT phosphorylation. We now want to investigate, using cell culture techniques, if 
these ligands have the ability to induce the expression of C/EBP~ protein. 
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Fig 4.14: Western Blot to investigate ifFSH and Areg can induce CIEBPP expression 
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Fig 4.14: Western Blot analysis of rat granulosa cells which were cultured overnight and then treated with 
extracellular ligands Follicle Stimulating Hormone (FSH) and Amphiregulin (Areg) to investigate if these 
ligands can induce CIEBPP expression. The non-treated samples (NT) on the left were cultured overnight and 
not treated with any ligand at all. The middle column of samples were cultured at 37°C overnight in media 
and then treated with FSH for 12,24 and 48 hours. The samples on the right were cultured at 37°C overnight 
in media and then treated with Areg for 24 and 48 hours. Beta Actin was used as a loading control. 
FSH and Areg display the ability to induce CIEBP~ when compared to non-treated cells 
(NT). This would suggest that C/EBP~ may be actively involved in ovarian cell 
proliferation and differentiation. Published data suggests that CIEBP~ is in fact involved in 
the cell cycle. Cyclin Dl and p21 can be regulated by C/EBP~ (Luedde et a12004). 
Pten: The negative regulator of the PI3K pathway 
In view of the importance of the PI3K pathway to the differentiation of ovarian granulosa 
cells and ovulation, we sought to identify the physiological role of Pten in developing 
ovarian follicles and its regulation of the PI3K pathway in granulosa cells. A conditional 
Pten knockout mouse strain was generated as described in Section 1.14. To generate a 
granulosa cell specific conditional knockout, Ptenfloxlflox mice were mated to Cre 
recombinase expressing mice, either the Amhr-2-Cre or the Cyp-19-Cre mouse. Amhr-2-
Cre and Cyp-19-Cre genotyping was carried out. 
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Fig 4.15 Genotyping for the Amhr2-Cre and Cyp19-Cre genotypes 
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Fig 4.15: showing the genotyping results of a representative number of mice tested for the Amhr 2-Cre and 
Cyp-19-Cre genotypes. The bands represent PCR amplified mouse tail DNA run out and visualised on a 1.5% 
agarose gel. The Amhr 2-Cre and Cyp-19-Cre genotypes are both represented by bands of approximately 300 
base pairs. Lane 8018 in the Cyp-19-Cre gel is a very immature mouse in which Cre is still present. This will 
eventually disappear. On the far right of the gel a molecular weight marker is shown. 
Pten mutations often lead to tumours in different tissues as the PI3K pathway is 
uncontrolled and hyperactive, however in the Pten conditional knockout (CKO) model, 
tumour formation does not occur, even at 10 months of age. Moreover, the 
PtenfloxlfloxCyp 19-Cre mice are actually fertile. Studies in our lab have shown that the Pten 
mutant mice give birth to ~20% more pups than wildtype in a 6-months breeding period. In 
super-ovulation experiments, the PtenfloxiflOXCyp19_Cre mice ovulate more oocytes than 
wildtype do, as examined at 16 hours after hCG treatment. When the mice were sacrificed 
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at 10 hours post-hCG treatment, on average 10-15 oocytes were recovered from the 
oviducts of Pten mutant mice, while no oocytes had been ovulated in wildtype. The blood 
estradiol and progesterone levels were shown to be no different between wildtype and Pten 
mutant mice, suggesting that the ovarian endocrine functions are not affected by Pten 
knockout (Fan et aZ2008a). The Pten CKO ovaries are exhausted quicker as a result of the 
PI3 kinase cascade being hyperactive and shown abundant corpora lutea at 3 months of age 
as opposed to only a few corpora lutea being present in wildtype mice at this age (Fig 4.16). 
To investigate this ovarian histology, some haematoxylin and eosin staining was carried out 
on wildtype and Pten CKO mouse ovaries. 
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Fig 4.16: Haematoxylin and Eosin staining of wild type versus Pten CKO paraffin wax 
embedded ovaries 
3 month old 
wildtype ovary 
showing few 
corpora lutea 
3 month old Pten 
eKO ovary 
showing abundant 
corpora lutea 
Fig 4.16: Hand E staining of 3 month old wildtype ovary (top) versus 3 month old Pten CKO ovary, both 
viewed under lOX magnification. 
After 3 months of age the ovaries of Pten CKO mice are larger and heavier and contain 
more corpora lutea than wild-type mice. Usually corpora lutea begin to regress by day 4 
post hCG. Recent studies in our lab have shown that the regression of corpora lutea in the 
Pten mutant ovaries is impaired and corpora lute a can still be present at day 15 post-hCG. 
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These observations provided the novel evidence that Pten appears to control the life-span of 
luteal cells and that its loss results in the persistence of luteal structures in the mouse ovary 
(Fan et al 2008a). In light of this knowledge we wanted to study how key intermediates, 
AKT and FOXO 1 in the PI3K pathway differed in wildtype mice versus the Pten CKO 
mouse strain. 
Fig 4.17: Western Blot showing PI3K pathway intermediates using wildtype versus 
Pten CKO mouse granulosa cells. 
Wildtype Pten CKO 
PMSG hCG hCG hCG PMSG hCG hCG hCG 
2hrs 8hrs 12hrs 2hrs 8hrs 12hrs 
Fig 4.17: hCG series showing that phosphorylated AKT and phosphorylated FOXOI are still present 8 hours 
post hCG injection in the Pten CKO whereas both are absent in wildtype mice at this time point. Total AKT 
was used as a loading control. 
pAKT and pFOXOl proteins are still present at 8 hours post hCG treatment in the Pten 
CKO where as both are gone in wildtype granulosa cells at this time point. This implies 
that the PI3K1AKT/FOXO cascade is still active at this stage in the Pten mutant as a result 
of the negative regulator of this pathway being knocked out in the granulosa cells. This 
uncontrolled cascade may result in the proliferation of granulosa cells and exhaustion of 
follicles in the Pten CKO ovaries. In addition to the PI3K1AKT/FOXO cascade, the Janus 
kinase/Signal transducer and activator of transcription (JAKIST AT) cascades pathway is 
also concerned with ovarian proliferation and differentiation. 
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The JAKISTAT pathways role in ovary development 
As explained in Section 1.10(iii), the JAKJST AT pathway functions In cell survival 
responses and is possibly linked to granulosa cell proliferation, differentiation and 
apoptosis. Stat5 is one of the downstream components of the JAKJST AT pathway. The 
mechanisms controlling the progression of granulosa cell fate (growth vs. atresia) and 
terminal differentiation (luteinisation) are not well understood. During the ovarian cycle 
numerous cytokines modulate gene expression and function, while luteinisation involves 
the acquisition of prolactin induced Stat5 responsiveness, a process requisite for 
maintenance of luteal cell function (Russel et al 1999). It has also been reported that 
luteinisation of PMSG primed ovaries by the administration of heG is accompanied by an 
induction of Stat5 protein (Ruff et al 1996). Some cell culture work was carried out using 
rat ovaries that had been treated with estradiol for 3 days to investigate whether 
extracellular ligands Amphiregulin, FSH, IL6 and Forskolin had the ability to increase 
pStat5 levels or not. Some of the samples were treated with FSHIT (Follicle Stimulating 
Honnone and Testosterone) resulting in further differentiated, more mature granulosa cells 
and were then treated with various ligands to determine if pStat5 levels showed any 
variation between immature and more developed granulosa cells. 
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Fig 4.18a: Western blot results of rat granulosa cells cultured overnight in media only 
and in media containing FSH and Testosterone 
Media Only FSllIT 
C FSH IL6 C C Areg IL6 Fo 
pSTAT5 
Beta Actin 
Fig 4.l8a: Rats were injected with estradiol for 3 consecutive days before granulosa cells were isolated and 
cultured overnight at 37°C in culture media only and in culture media containing Follicle Stimulating 
Hormone and Testosterone (FSHlT). FSH and IL6 were added to media only samples for lO minutes. 
Amphiregulin (Areg), Interleukin 6 (IL6) and Forskolin (Fo) were added to FSHIT samples for 10 minutes. 
Control lanes (C) were not treated with any ligands. Beta-Actin was used as a loading control. 
Fig 4.18b: Western blot results of rat granulosa cells cultured overnight and then 
treated with extracellular ligands 
AREG FSH 
C 5 10 30 5 10 30 5 
IL6 
10 30 
pSTAT5 
Beta Actin 
Fig 4.l8h: Rats were injected with estradiol for 3 consecutive days before granulosa cells were isolated and 
cultured overnight in culture media at 37°C. Ligands Amphiregulin (Areg), Follicle Stimulating Hormone 
(FSH) and Interleukin 6 (IL6) were added for 5, lO or 30 minutes just before cells were harvested. The 
control lane (C) on the left was not treated with any ligands. Beta-Actin was used as a loading control. 
The western blot results from Figure 4.18 demonstrate that IL6 has the ability to induce 
STAT5 phosphorylation when compared to granulosa cell samples that have not been 
treated with any ligand and those treated with AREG and FSH. Most phosphorylation 
occurs after 10 minutes of treatment with IL6. Amphiregulin, Forskolin or FSH cannot 
induce ST A T5 phosphorylation. FSHIT treatment does not result in a higher level of 
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STAT5 phosphorylation indicating pSTAT5 levels are independent of the stage of 
development of the granulosa cells. 
RaslRaflMEKiERK pathways role in ovary development 
In conjunction with the PI3K1AKT/FOXO pathway, FSH also has the ability to stimulate 
the RasIRafl/MEKlERK1I2 cascade. As mentioned in the introduction, Section 1.1O(ii), 
this pathway is also concerned with ovarian cell proliferation and differentiation through 
FSH signal transduction. FSH can activate the (Extracellular Signal Related Kinase) ERK 
pathway in a unique time dependant and synergistic manner. We have already looked at 
Areg, FSH and IL6 ability to induce AKT phosphorylation and C/EBP-~ expression, it was 
now necessary to assess how these ligands functioned in activating ERK pathway 
intermediates. Cell culture work was carried out using granulosa cells which were isolated 
from estradiol treated rat ovaries. 
Fig 4.19a: Western blot results of rat granulosa cells cultured overnight and then 
treated with extracellular ligands 
AREG 
C 5 10 30 5 
FSH 
10 30 5 
IL6 
10 30 
... Beta Actin 
Fig 4. 19a: The left control lane (C) was not treated with any ligand. Each of the other lanes were treated with 
Amphiregulin (Areg), FolIicle Stimulating Hormone (FSH) and Interleukin 6 (IL6) ligands respectively for 5, 
10 and 30 minutes . Beta actin was used as a loading control. 
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Fig 4.19b: Western blot results of rat granulosa cells cultured overnight and then 
treated with extracellular ligands 
FSH IL6 FSH 
c 10 10 C 5 10 30 
pERK 
Beta Actin 
Fig 4.J9b: The lanes on the left were treated with Follicle Stimulating Hormone (FSH) and Interleukin 6 
(IL6) for 10 minutes. The other lanes were treated with Follicle Stimulating Hormone (FSH) for 5, 10 and 30 
minutes. The control lanes (C) were not treated with any ligands. Beta actin was used as a loading control. 
Areg, IL6 and FSH all display the ability to induce the phosphorylation of ERK when 
compared to the control lane which has not been treated by any ligand at all. IL6 is the 
strongest inducer, followed closely by Areg and then FSH. IL6 and FSH show similar 
induction patterns, showing highest ERK phosphorylation at 5 and 10 minutes post ligand 
treatment and then decreasing at the 30 minute time point. Areg shows a similar level of 
ERK phosphorylation at 5, 10 and 30 minute time points. 
FSHIT causes better induction of the LH receptor and improves cytokine 
cleavage. Cells differentiate more after FSH and testosterone treatment so are more 
mature. To investigate if further differentiated, more mature cells respond differently to 
such ligands (Areg, IL6, Fo), rat granulosa cells were incubated overnight at 37°C in media 
containing FSHIT and phospho-ERK expression was measured. 
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Fig 4.20: Western blot results of rat granulosa cells cultured overnight in FSH/T 
containing media and then treated with extracellular ligands 
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Fig 4.20: Rat granulosa cells cultured overnight in Follicle Stimulating Hormone/Testosterone (FSHlT) 
containing media. The control lanes (C) were not treated with any ligands. The other lanes were treated with 
Amhiregulin (Areg), Interleukin 6 (IL6) and Forskolin (Fo) for 10 minutes. Beta actin was used as a loading 
control. 
The addition of FSHIT to the media did not necessarily yield better phosphorylation of 
ERK. Again IL6 and Areg display the ability to induce pERK protein levels. However, 
forskolin does not result in an induction of pERK expression when compared to the control 
lanes. Perhaps more mature granulosa cells are not responsive to forskolin. As mentioned 
in the introduction Section I.IO(i)(ii), Ras functions to activate both the PI3K1AKT/FOXO 
and Ras/Raf/MEKIERK pathways. Gene targeting studies have determined the K-Ras 
isoform to be essential for normal development in mice as opposed to other H-Ras and N-
Ras isoforms (Koera K et al 1997). Some reports show that binding between Ras and down 
stream Raf is strengthened in the fibroblast cells of the K-ras GI2D knock-in mouse strain 
(Tuveson et al 2004) where as other reports suggest that K-ras GJ2D models induce 
tumourigenesis by activating PI3K1AKT and p38 MAPK cascades (Cespedes et al 2006). 
Haematoxylin and Eosin staining of ovary sections from wildtype and K-ras GJ2D knock in 
mice was carried out to investigate the histological difference between the two (Fig 4.21). 
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Fig 4.21: Haematoxylin and Eosin staining of wild type ovary versus K_rasG12D_ 
Amhr2-Cre knock-in ovary 
Wildtype hCG 48 hrs 
Corpus luteum 
which has ovulated 
K-rasGI2D-Amhr2-Cre hCG 48 hrs 
Corpus luteum with 
trapped oocyte inside 
Fig 4.21: H and E staining of wild type ovary on the left which has been treated with hCG for 48 hours and K-
rasG12D-Amhr2-Cre mutant ovary on the right which has also been treated with hCG for 48 hours (Fan et al 
2008b). 
Ovaries of immature KrasG 12D mutant mice did not exhibit tumourigenic cells but instead 
the ovaries contained numerous, abnormal, follicle-like structures, devoid of mitotic and 
apoptotic cells as well as cells expressing granulosa cell marker genes. Most follicles that 
proceeded to antral stage failed to ovulate and exhibited impaired responses to PMSG and 
hCG. Fan et al have shown that these strange corpora lutea-like structures with trapped 
oocytes inside are negative for proliferating cell nuclear antigen (PCNA), a mitotic marker. 
Bromodeoxyuridine (BrdU) is also gone in this knock in model (Fan et al 2008b). BrdU is 
commonly used in the detection of proliferating cells in living tissues. BrdU can be 
incorporated into the newly synthesised DNA of replicating cells during the S phase of the 
cell cycle, substituting for thymidine during DNA replication. 
Previous work done in the lab included carrying out a microarray on these 
K-ras knock-in mice. Results showed Cyclin A, Cyclin E and E2Fl genes were all 
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decreased by 10 fold. Each of these cyclin genes are involved with the 0 1 phase of the cell 
cycle. E2F! can mediate both cell proliferation and p53/dependentlindependent apoptosis 
(NCBI database). Since each of these genes are associated with cell progression through 
the cell cycle and each one was decreased on the microarray, it suggested that the K-ras 
knock-in models consisted of abnormal, non-mitotic and non-apoptotic cells. 
Inappropriate, premature expression of Kras in granulosa cells blocks the granulosa cell 
differentiation pathway and leads to the persistence of these corpora lutea-like structures 
(Fan et al 2008b). These structures appear to be senescent. 
To investigate if these knock-in mIce models were associated with 
tumourigenesis, a variety of tumour suppressor genes were investigated: p15, p16, p19. 
The p15(INK4B) gene encodes a CDK inhibitor. p15 is critically involved in cell cycle 
regulation and can be hyper-methylated in Acute Myloid Leukaemia. Functional 
inactivation of the retinoblastoma and p53 pathways appears to be a rite of passage for all 
cancerous cells and results in disruption of cell-cycle regulation and deactivation of the 
apoptotic response that normally ensues. The INKa/ARF locus sits at the nexus of these 
two growth-control pathways, by virtue of its ability to generate two distinct products: the 
p 16INKa protein, a cyclin-dependent kinase inhibitor that functions upstream of RB; and the 
p1~RF protein, which blocks MDM2 inhibition of p53 activity. This 'one gene-two 
products-two pathways' arrangement provides a basis for the prominence of INKa/ARF in 
tumourigenesis (Chin et al 1998). p16 inhibits CDK4 and commonly functions in cell 
cycle 0 1 control. This gene increases in cells with age and accumulates and modulates 
specific age-associated human stem cell functions (Jansen et al2006). 
The human KIT ligand gene, known also as human stem cell factor, is the 
ligand of the c-kit transmembrane tyrosine kinase receptor (KIT). This ligand-receptor 
interaction is known to play important roles in mouse germ cell migration and proliferation. 
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In preparation for ovulation, paracrine communication between the preovulatory follicle 
and overlying theca/stromal cells and ovarian surface epithelium must take place to 
facilitate the degradative and apoptotic events associated with ovulation. Kit tyrosine 
kinase receptors and their ligand kit ligand are expressed within ovarian follicles, and 
ligand-induced receptor activation appears to account for some of the cell - cell interactions 
important for oocyte development (Driancourt et al 2000). As a consequence of this, the 
kit ligand gene was also investigated in the knock-in mouse model to see if it was down-
regulated. 
Firstly linearisation assays were carried out to determine the best number of 
cycles to use for these particular genes of interest within the ovary. m-RNA was extracted 
from mouse cell culture samples and an RT-PCR carried out to produce c-DNA. The 
optimum number of cycles was then determined using this c-DNA by performing a PCR 
using radioactively 32p dCTP. Once the PCR was carried out these samples were then 
loaded on a 1.5% acrylamide gel and dried on a gel dryer. This dried gel was then placed 
in a cassette and exposed to an x-ray film in the darkroom similar to how western blots are 
developed. 
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Fig 4.22: Linearisation assay to determine optimum number of PCR cycles using a 
two step PCR method 
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Fig 4.22: Wildtype mouse ovaries were used to determine the linear range of particular genes of interest 
associated with senescence. 
Judging from the results in Fig 4.22, it appears the optimum number of cycles for kit ligand 
and pI5 is 28. The optimum number of cycles for pI6 is 34 and for pI9 is 32. It was now 
possible to go ahead and compare how wildtype ovary lysates compared to K_rasGI2D_ 
Amhr2-Cre mutant ovary lysates and to see if tumour suppressor genes are in fact altered in 
the mutant ovaries as a result of these strange corpora lutea like structures with trapped 
oocytes inside. 
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Fig 4.23: Two step peR method to compare markers of senescence between wildtype 
and the K_rasG12D -Amhr2-Cre knock-in mice 
Wildtype K_rasG12D -Amhr2-Cre 
2 3 1 2 3 
ligand 
Fig 4.23: Radioactive PCR using 32p dCTP. The three samples to the left ofthe red line are wildtype ovary 
lysates from three different mice that have been treated with hCG for 48 hours. To the right of the red line are 
three ovary lysate samples for three different K_rasG12D -Amhr2-Cre mutant mice that have been treated with 
hCG for 48 hours. 
Kit ligand expression in the Kras mutant mouse does not seem to be affected. During early 
folliculogenesis, kit together with kit ligand controls oocyte growth and theca cell 
differentiation, and protects preantral follicles from apoptosis. Formation of an antral 
cavity requires a functional kit-kit ligand system. In large antral follicles, the kit-kit ligand 
interaction modulates the ability of the oocyte to undergo cytoplasmic maturation and helps 
to maximise theca androgen output. Hence, many steps of oogenesis and folliculogenesis 
appear to be, at least in part, controlled by paracrine interactions between these two 
proteins (Drain court et al 2000). An increase in tumour suppressor genes was perhaps 
expected in the Kras mutant mice samples as these mice are non-mitotic and display 
senescent qualities. The Kras mutant however showed a decrease in pi5 and pi9 
indicating there must be some other mechanism taking place that induces senescence. pi6 
expression remained relatively similar to the wildtype. It has been shown that the initiation 
of oocyte growth, which seems to lead follicle growth, is associated with diminished p16 
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expression in the mouse ovary. Increased expression of the p 16 gene occurs early in the 
development of ovarian carcinomas and then levels begin to decrease (Chiesa-Vottero et al 
2007). 
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5.0 DISCUSSION 
Cell proliferation and differentiation is necessary for the progressive growth of ovarian 
cells. Although granulosa cells are the main cell type within the ovary, granulosa cell 
tumours are extremely rare, accounting for ~5% of all ovarian cancer. This suggests that 
there is a very strict, controlled regulatory system influencing the growth and 
differentiation of these cells. The cell cycle itself is regulated by the balance between 
signals which promote the cell cycles progression and apoptotic or inhibitory signals which 
stop the cell cycle. These signals are as a result of interplay between many signalling 
pathways. This project looked mainly at two such pathways, the PI3K1AKT/FOXO and the 
Ras/RaflMEKIERK pathway. This study provided the novel insight into the expression 
pattern of key components from these cell signalling pathways, allowing us to investigate 
which component was expressed at which particular stage of follicular growth during 
normal ovarian development. 
Cell cycle regulators playa big role in ovarian follicular development and 
determine if ovarian cells are to proliferate, perhaps resulting in ovulation, or differentiate 
into luteal cells and eventually become atretic. Cyclin D2 levels do not seem to increase or 
decrease throughout the hCG series (Fig 4.2a). This would imply that Cyclin D2 plays a 
critical role in all aspects of ovarian cell development. Whether the cells are growing to a 
pre-antral stage, as is the case with the PMSG treated cells or whether the cells are more 
developed and differentiating into luteal cells after hCG treatment, there is no major change 
in Cyclin D2 protein level. It has previously been shown in the absence of Cyclin D2, the 
mitotic activity of granulosa cells is markedly impaired and growing follicles remain small 
with few (usually only one or two) layers of granulosa cells (Robker et al 1998a). Despite 
the reduced number of cells, these cells respond to LH in a normal pattern of 
differentiation. For instance, progesterone receptor and prostaglandin synthase-2, two 
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regulators of ovulation (Richards JS 1994) (Sirois J et al 1992a) are induced by the LH 
surge in a pattern similar to that of normal ovulating follicles (Robker et al 1998a). Yet the 
"preovulatory" follicles of cyclin D2 null mice do not ovulate. This raises the intriguing 
question whether or not the number of granulosa cells is critical for stimulating some event 
associated with ovulation. The temporal expression pattern for p27Kipl at 16 hours post 
hCG treatment (Fig 4.2a) suggests that a second mechanism by which LH terminates 
granulosa cell proliferation is by increasing the level of this CDK inhibitor. In addition, the 
increase in p27Kipl may control some aspect of granulosa cell differentiation or 
maintenance of luteal cell differentiation. In the absence of p27Kip1 , differentiation 
characteristic of luteinisation appears impaired (Robker et al 1998a). However, despite the 
key role of p27Kipl in checking cell cycle progression and its presence in granulosa cells 
and luteal cells, the absence of p27Kip1 does not lead to rampant uncontrolled proliferation 
of these cells. Thus, other inhibitors of cell division appear to be more critical during 
follicular growth. Considering the immunofluorescence pictures (Fig 4.3), p27Kip1 is not 
present in every growing follicle 48 hours after PMSG treatment. Some of the larger 
follicles stain intensely for p27Kipl but the smaller, less developed primary follicles do not 
show this intense staining pattern. Once cells begin to luteinise after 16 hours hCG 
treatment, the p27Kipl staining pattern is more uniform. Luteal cells and apoptotic follicles 
stain positively for this cell cycle inhibitor. The cell cycle has somewhat stopped once 
granulosa cells reach this stage of development and differentiation has commenced. 
Oxidative stress can activate the MSTI SAPKlJNK apoptotic pathway. This 
can result in the phosphorylation of FOXO 1 promoting nuclear translocation and inducing 
cell death (Lehtinen et al 2006). Non treated, developing and luteinising follicles all 
display a similar protein level of these apoptotic markers (Fig 4.4). Both these markers 
show positivity in the theca cells of follicles showing quite a similar staining pattern (Fig 
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4.5). In each estrous cycle, only one or a few follilces are successfully ovulated so more 
than 90% of the recruited follicles stop growth at various stages of development and are 
eliminated by apoptosis. This phenomenon is called follicle atresia and is still not very 
well understood. The MSTI and pSAPKlJNK results imply that follicles rely on apoptotic 
signals other than these two apoptotic markers during follicle atresia. 
The PI3K/AKT/FOXO pathway is at the heart of one of the major pathways 
of intracellular signal transduction. The PI3K signalling pathway has been shown to be 
required for an extremely diverse array of cellular activities, most notably cellular 
proliferation and survival. As a consequence of this, components of the pathway are high 
on the list of most pharmaceutical companies as good targets for cancer therapy. It has also 
been demonstrated that up-regulation of the PI3K pathway by chronic treatment with hCG 
can induce changes in ovaries that stimulate polycystic ovary syndrome (POS) (Lima et al 
2006). The PI3K subunit pllOy is mutated in many cancers, causing it to be more active 
(Ward et al 2003). Downstream of PI3K, mTOR and AKT are being explored as potential 
targets for cancer therapy and perhaps POS treatment. Better targets in the 
PI3K1AKT/FOXO pathway are constantly been looked for as toxicity is often an issue in 
drug design. Before proposing to establish potential drug targets within the pathway, it is 
important to understand the expression of pathway components during normal ovarian 
development. Once FSHlLH binds its receptor, ras can activate the PI3K pathway by 
directly binding to the IGF receptor and resulting in the activation of pI lOy, the catalytic 
subunit ofPI3K (Fig 1.11). pI lOy protein levels show a slight decrease at the 16 hour time 
point, after ovulation has occurred (Fig 4.7). The PI3K pathway is perhaps not as active at 
this time point as granulosa cells are differentiating into luteal cells as opposed to 
proliferating. The next step in the pathway is the sequential phosphorylation of PDK and 
AKT. pPDKI levels remain relatively constant, showing a slight increase once hCG is 
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administered at the 2 and 4 hour time points (Fig 4.7). The initiation of the PI3K pathway 
appears to be most important once heG is administered. The phosphorylation of AKT 
occurs once PMSG is administered, FOXOI being a downstream target of AKT shows a 
later phosphorylation induction at 2 hours post heG treatment (Fig 4.8a). As mentioned, 
the functional FOXO 1 remains in the nucleus promoting apoptosis but when 
phosphorylated by AKT is translocated to the cytoplasm and rendered inactive. This 
phosphorylation is important once heG is administered and lasts right up to the 16 hour 
time point after where ovulation has occurred. pFOXO 1 therefore plays a role in early 
follicular development right up to the preovulatory, ovulatory and luteinisation stage (Fig 
4.8a). Total FOXOI is present at high levels in the non treated and PMSG treated samples, 
promoting apoptosis at this stage (Fig 4.8a). This constant translocation and 
phosphorylation of FOXO in a time dependent manner appears to be essential for the 
growth and development of follicles as well as ovulation and luteinisation. If we consider 
the immunofluorescence staining in Figure 4.9 we can see the pFOXO 1 displays a more 
nuclear punctuated cytoplasmic staining pattern in the PMSG treated sections and shows a 
more cytoplasmic staining pattern in more mature luteal cells. This higher abundance of 
pFOXOl at 16 hours post heG treatment than in the PMSG treated sample again solidifies 
the idea that pFOXO 1 is playing a role in at the luteinisation stage. The low levels of 
pFOXO 1 at the PMSG time point in both the western and the immunofluorescence pictures 
(Fig 4.8a, Fig 4.9), implies that the intense phosphorylation of this key component is not 
essential at early stages of follicular development. P70S6k is another possible target of 
AKT. Phospho-P70S6k (pP70S6k) levels show a slight increase once heG is administered 
which drops back to NT/PMSG treated levels at 16 hours post heG (Fig 4.8a). The 
phosphorylation of P70S6k therefore is a key event in the growth of follicles up to the 
ovulatory stage but is not needed in such abundance once luteinisation begins to occur at 
the 16 hours post heG time point. 
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Rat granulosa cell culture work was carried out to investigate how isolated 
granulosa cells reacted to extracellular ligands such as AREG, FSH, IL6 and Fo. AREG is 
a growth factor involved in cancer development, but its potential role in signalling in the 
gonads is still obscure. It has been reported that basal expression of this growth factor is 
evident in human granulosa cells obtained from women treated for in vitro fertilisation. 
Expression of these factors was elevated concomitantly with elevation of progesterone 
production in these cells upon stimulation with LH, and to a lesser extent with FSH. 
AREG gene expression was dose- and time-dependent when measured subsequent to LH 
stimulation (Freimann et al2004). Moreover, Fo which activates adenylate cyclase, was as 
efficient as LH in stimulating expression of these growth factors. It is suggested that 
upregulation of AREG expression is part of the signal transduction pathway which leads to 
ovulation and luteinisation in the human ovary. IL6 can also directly influence FSH 
differentiating functions of ovarian granulosa cells. All three ligands show the capacity to 
induce AKT phosphorylation to more or less the same degree that FSH does (Fig 4.10). 
The more mature granulosa cells which have been treated with FSH and Testosterone 
display a greater level of pAKT protein after treatment with Fo, AREG and IL6 (Fig 4.11) 
than the granulosa cells which have been cultured in culture media only (Fig 4.10). These 
results suggest that these three ligands may be players in signalling pathways that influence 
granulosa cell proliferation and differentiation such as the PI3K pathway and the ERK 
pathway, perhaps having a bigger role influencing the more mature granulosa cells than the 
immature developing cells. 
C/EBP~ mRNA expreSSIOn is induced rapidly in granulosa cells 30 
minutes after stimulation with LHlhCG in vivo (Sirios et al 1993). This indicates the 
C/EBP~ gene is an immediate target of LH-receptor signalling. It has recently been shown 
that C/EBP~ is expressed upon induction of differentiation of preadipocyte cells, initiating 
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a transcription cascade. CIEBP~ immediately undergoes a priming phosphorylation on 
Thr188 by MAPKIERK. The acquisition of DNA binding and trans activation capacity of 
C/EBP is delayed until further phoshorylation on Serl84 and Thrl70 by glycogen synthase 
kinase-3~ (GSK3~) occurs. Phosphorylation by GSK3~ induces S phase entry and thereby 
mitotic clonal expansion, a requirement for terminal differentiation (Li et al 2007). In this 
project CIEBP~ was induced at 2 hours post hCG treatment and remained until 5 days after 
hCG had been administered (Fig 4.13). This indicates that C/EBP~ is important in events 
surrounding the cell cycle ie. growing follicles where granulosa cells move to form the 
antrum and also at the granulosa cell differentiation into luteal cell stage. FSH and AREG 
both showed the ability to induced C/EBP~ gene expression (Fig 4.14). This would 
suggest the CIEBP~ is a downstream target of the FSHlLH receptor. 
PTEN is the negative regulator of the PI3K pathway. Pten CKO 
mice display abundant corpora lutea at 3 months of age (Fig 4.16). The PI3K pathway is 
known to govern cell division, survival, size and apoptosis inhibition (Sulis M.L et al 
2003). Without mural granulosa cell expression of the tumour suppressor PTEN, 
uncontrolled proliferation, evasion of apoptosis and possible tumourigenesis could prevail 
in the ovary as a result of the over activation of the PI3K cascade. PTEN under normal 
circumstances is expressed intensely in the mural granulosa cells and theca cells (Fan et al 
2008a). This identifies PTEN to have an important role in cell signalling and morphology 
in these cells. In wildtype mice PTEN expression is constant over all stages of 
development. The presence of corpora lutea at 3 months of age would suggest that the 
conditional knock-out of Pten in granulosa cells did not alter follicular development, 
ovulation or luteinisation. The PI3K pathway components were not altered or 
dysfunctional in the Pten CKO but just uncontrolled and overactive as a result of this. As 
seen in our study (Fig 4.8) and also reported previously in this laboratory (Richards et al 
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2002), normally activation of the PI3K pathway by FSHlPMSG has shown to increase the 
expression of the pro-apoptotic factor FOXO 1. Activated PI3K can phosphorylate AKT. 
Subsequent phosphorylation of downstream FOXO by pAKT inactivates the active FOXO 
by restricting its nuclear localisation (Richards et al 2002). In the Pten CKO it could be 
hypothesised that the transcription factor FOXO could not transcriptionally activate the cell 
cycle inhibitor p27kip1 resulting in excess growth and proliferation of the ovarian cells and 
hence abundant corpora lutea and ovary exhaustion. pAKT and pFOXO is still present 8 
hours post hCG injection in granulosa cells of the Pten CKO model but not in the wildtype 
mouse granulosa cells providing further evidence that the PI3K pathway is over-active in 
the CKO (Fig 4.17). The phosphorylation of AKT is highest after 2 hours of hCG 
treatment in both whole ovary lysates (Fig 4.8a) and isolated granulosa cells (Fig 4.17) of 
wildtype mice. PMSG treatment results in the strong phosphorylation of AKT in wildtype 
ovary lysate samples (Fig 8a) but induces this phosphorylation to a less extent in wildtype 
isolated granulosa cells (Fig 4.17). Granulosa cells from the Pten CKO mouse show 
significant pAKT protein levels after PMSG treatment which lasts up to 8 hours post hCG. 
FOXOI phosphorylation also is sustained for longer in the Pten CKO granulosa cells than 
isolated granulosa cells from wildtype mouse. The decline of pFOXOI is greater in 
wildtype granulosa cells (Fig 4.17) than in whole ovary lysates (Fig 4.8a). pFOXO 1 is 
present at a significantly lower level in granulosa cells at 8 and 12 hours post hCG 
treatment when compared to pFOXO 1 levels in whole ovary lysates. The phosphorylation 
of FOXO 1 at 8 and 12 hours post hCG must therefore playa more important role in other 
cells of the ovary ie. theca cells and cumulus cells, than in isolated granulosa cells. 
However, both figures 4.8a and 4.17 both show the most intense phosphorylation of 
FOXO 1 at the 2 hours post hCG timepoint. The Pten CKO granulosa cells in fig 4.17 
exhibit enhanced responses to PMSG, hence the higher level in PMSG lane. We could 
hypothesis that the levels of total FOXO are already down in these mice by the time of 
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hCG, hence the poor response to hCG compared to wildtype granulosa cells. In the CKO 
the cells remained functional and progressed to the next stage of ovulation, differentiating 
into luteal cells. LH was released at the luteal stage of development causing a decrease in 
expression of the pro-apoptotic factor FOXOI favouring cell survival. Eventually when the 
granulosa cells where induced to undergo luteinisation they possibly became resistant to 
apoptosis, pro apoptotic factors were lost and luteinisation factors like p21 and Sgk 
acquired, thus possibly giving rise to a luteal cell pre-tumour phenotype yet with relatively 
normal function. It is quite probable that this phenotype will eventually reach a 
tumourigenic stage that will impinge greatly on ovarian function. 
The JAKISTAT pathway functions in cell survival responses and is 
possibly linked to granulosa cell proliferation, differentiation and apoptosis. Activation of 
downstream components of this pathway, ST A Ts, is complex and involves many factors 
and in some situations gene regulation may be dependent on signal duration, indicating that 
the deactivation of signals is as important as the ligand-dependent activation in establishing 
and maintaining tissue responsiveness. Stat 5 null mice fail to produce corpora lutea at all 
(Russell et aI1999). Ligands such as FSH, IL6, AREG and Fo were used to treat cultured 
granulosa cells to investigate which ligand, if any, displayed the ability to induce the 
phosphorylation of Stat5. IL6 was the only ligand showing the ability to induce pSTAT5 
and there was not difference in pST A T5 protein levels in granulosa cells cultured in media 
alone versus further differentiated granulosa cells which had been treated with FSH/T 
overnight (Fig 4. 18a). Treatment with IL6 resulted in an increase in pST A T5 levels at 5 
and 10 minutes post treatment, decreasing slightly at 30 minutes (Fig 4. 18b). IL6 therefore 
appears to works in a time dependent manner. 
As mentioned previously, the Ras/Raf/MEKIERK pathway plays a major 
role in cell proliferation and differentiation. The ability of ligands such as FSH, IL6 and 
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AREG were investigated to determine their ability at inducing ERK phosphorylation. All 
ligands showed the ability to induce levels of pERK, IL6 showing the strongest transient 
induction at the 5 and 10 minute post treatment time points before decreasing slightly after 
30 minutes of treatment (Fig 4. 19a). FSH displays a similar induction pattern while AREG 
retained the same levels of pERK. induction at 5, 10 and 30 minutes post treatment (Fig 
4. 19a). Forskolin did not induce the phosphorylation of ERK (Fig 4.20). Cells treated 
with FSHITestosterone in order to make them more mature did not show any greater 
induction of pERK than the less mature cells (Fig 4.20). This indicates that Fo is not 
capable of inducing the RasIRaflMEKiERK. pathway and the induction of pERK. as a result 
of FSH, IL6 or AREG treatment is not effected by granulosa cells stage of development. 
Another side to this study aimed to examine the location and some of the 
effects of constitutively active K-ras on ovarian morphology and function. Recent work 
done in the Richards lab indicates that ovaries expressing constitutively active K-ras are 
considerably larger in size when compared to wildtype ovaries. Microscopic examination 
of ovarian morphology via H&E staining showed that ovaries expressing constitutively 
active K-ras demonstrated aberrant tumour like follicles. 48 hours post hCG treatment the 
K-ras mutant showed corpora lutea with trapped oocytes inside (Fig 4.21). 
Immunohistochemistry and in-situ hybridization experiments have also demonstrated the 
lack of vital ovarian FOXOI protein expression and Lrh-1 mRNA expression in these 
aberrant follicles (Fan et al 2008b). As FOXO protein transcription factors are known to 
play a vital role in the transcription and activation of pro and anti apoptotic factors 
(Richards et al 2002), the absence of FOXO may in part create an imbalance in cell growth 
favouring tumourigenesis and abnormal ovarian function. The observation that these K-ras 
mutant ovaries showed some morphologically normal follicles as well as some tumour-like 
follicles and that the only apparent fault of these morphologically normal follicles was an 
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inability to progress to the next stage of ovulation and luteinisation when induced, indicated 
a possible hormone receptor complication. The K-ras knock-in models consist of 
abnormal, non-mitotic and non-apoptotic cells. Their phenotype is one of senescence. 
Some tumour suppressor genes as well as kit ligand, a gene associated with oocyte 
development, was investigated in the hope of elucidating the origin of these strange corpora 
lutea like structures. Kit ligand and pi6 showed similar results to wildtype models 
suggesting the problem is not associated with their expression (Fig 4.23). pi5 and pi9 are 
both decreased in the mutant K-ras ovaries. Perhaps this decrease in tumour suppressor 
genes is the reason some K-ras mutants have gone on to develop tumours (Fan et aZ2008b). 
As these K-ras knock-in ovaries demonstrated tumour like follicles with highly condensed 
granulosa cells, absent follicle cavities and de-shaped oocytes pushed to the periphery, it 
was suggested that the abnormal structure identified translated into abnormal ovarian 
function and this then possibly related to a compromised fertility status (Fan et aZ2008b). 
In conclusion, the PI3K1 AKT/FOXO pathway is undoubtedly a core 
pathway involved with follicular growth. Granulosa cell proliferation and luteal cell 
differentiation rely on signals from this pathway. Extracellular ligands can induce the 
activation of downstream targets in the PI3K pathway. Generating a Pten CKO mouse 
strain resulted in a luteal cell pre tumour phenotype in which the PI3K pathway was over-
active and ovaries were exhausted earlier than would happen in a wildtype mouse. 
Engineering ras to be constitutively active in the mouse ovary results in ovulation 
malfunction and fertility problems. Considering these results, it is important for us to 
understand the time specific and downstream target specific nature of components in both 
the PI3K1AKT/FOXO pathway and the Ras/Raf/MEKIERK pathway. From a drug design 
point of view, although no downstream inhibitors have reached trials, transcription factors 
have recently gained interest as the most direct and mechanistically relevant targets of the 
ERK pathway. Already a number of small kinase inhibitors against Raf and MEK have 
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entered clinical development. This has occurred despite the importance of these kinases in 
so many processes unrelated to cellular proliferation. Ultimately, as the pathway is further 
revealed, novel components will provide the researcher with new therapeutic strategies. 
This novel insight into the expression pattern of components from molecular pathways such 
as the PI3K and the ERK pathway in normal ovarian development may help us on the 
journey of drug design to potentially target and treat polycystic ovarian syndrome, ovarian 
cancer or perhaps even infertility. 
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